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Abstract 
Molecules that bind to tubulin and disrupt tubulin dynamics are known as microtubule 
targeting agents. Treatment with a microtubule targeting agent leads to cell cycle arrest 
followed by apoptosis. Tubulin inhibitors have been highly effective in the clinical 
treatment of a variety of tumors and are being investigated for treatment of several other 
diseases. Currently, all FDA approved microtubule inhibitors bind to β-tubulin. Given the 
overall success of tubulin-binding agents in anticancer chemotherapy, α-tubulin is an 
attractive and unexplored target. Herein, we will discuss the natural product pironetin, the 
only compound known to bind α-tubulin. 
Despite the potent in vitro activity against ovarian cancer cell lines both sensitive and 
resistant to current chemotherapeutics, pironetin was only marginally effective at high 
doses in mice and resulted in severe weight loss, indicating poor 
pharmacokinetic/pharmacodynamic (PK/PD) properties and significant off target 
toxicities. The research presented in this dissertation seeks to improve the therapeutic 
properties of pironetin by addressing the PK/PD and off target binding concerns. In Chapter 
2, we determined that pironetin has a short half-life in liver microsomes and identified 
pironetin’s major site of metabolism in human liver microsomes to be the unconjugated 
olefin utilizing tandem mass spectrometry. We then confirmed the identity of the major 
metabolite as epoxypironetin through semi-synthesis and identified a very minor 
metabolite, demethylpironetin, with similar potency as pironetin.  
iv 
 
With the knowledge that the unconjugated olefin is the major site of metabolism, we 
sought to block this site through total synthesis. We thus completed the total synthesis of 
4-fluorophenyldemethylpironetin (19 linear steps, 31 total steps) with the goal of 
improving the metabolic stability while maintaining potency (Chapter 3). This represents 
the first total synthesis of demethylpironetin analogs. Finally, in Chapter 4 we describe our 
efforts to establish a proof-of-concept method for the targeted delivery of pironetin to 
ovarian cancer cells by targeting the folate receptor. Our results suggest that pironetin 
conjugates do not enter the cell in a folate receptor mediated manner, therefore 
necessitating exploration of addition means of targeting for pironetin delivery.  
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Chapter 1: Introduction 
 
This chapter was adapted from: Coulup, S.K. & Georg, G.I. Bioorg. Med. Chem. Lett., 
2019, 29, 1865-1873. 
 
1.1 General Background  
Cancer is the second leading cause of death in the United States and includes at least 
100 distinct types characterized by abnormal cell growth caused by the combination of 
mutations that alter cell signaling and survival.1 Tumorigenesis, or the conversion of 
normal, healthy cells into their malignant derivatives, is now understood to be a multistep 
process, however, many dimensions of cancer, and what separates a benign tumor from a 
malignant tumor, are still far from understood.2, 3 The progression of tumorigenesis occurs 
due to several acquired capabilities that confer a growth advantage, similar to Darwinian 
evolution.4 While the vast amount of research and resources put towards developing cancer 
therapeutics and earlier detection methods has provided a great number of successes, many 
cancer types are still largely untreatable. In addition, many cancer patients relapse 
following chemotherapy, malignancies metastasize, and many develop resistance to 
current therapeutics. 
Over the past 50 years, the progress made in the treatment and diagnosis of tumors has 
been astounding, however many cancers are still not diagnosed until late stages of the 
disease. Ovarian cancer is one such variety. A total of 25,000 cases of ovarian cancer are 
expected to be diagnosed this year and more than half of the women diagnosed will die 
within five years. This is predominantly because the majority of patients presenting with 
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ovarian cancer (60%) are diagnosed in the late stages in which the cancer has already 
metastasized.5 In addition to improved diagnostics for earlier detection of ovarian cancer, 
there is a critical need to develop therapeutics with novel mechanisms of action that can be 
used to treat women whose ovarian cancer has become resistant to current therapeutics.  
1.2 Current Chemotherapeutics: Microtubule Targeting Agents  
The current treatment options for patients presenting with ovarian cancer are relatively 
few. If the tumor can be debulked, patients will first undergo cytoreduction to surgically 
remove as much tumor as possible and follow up with chemotherapy. The combination of 
the DNA crosslinking agent carboplatin and the microtubule targeting agent paclitaxel has 
been the first line of treatment for the past three decades. Despite the high initial response 
rate, most patients relapse and become resistant to currently available chemotherapeutics, 
highlighting the critical need for the discovery of new therapeutics, including microtubule 
targeting agents.6  
Microtubules are polymers of α- and β-tubulin protein heterodimers that associate 
longitudinally into protofilaments. Lateral assembly of protofilaments forms the 
microtubule, which can be further elongated or shortened by single α- and β-tubulin 
heterodimers (Figure 1.1A).7 The slow, sustained polymerization and rapid 
depolymerization, called dynamic instability, is fueled by GTP hydrolysis and occurs at 
both ends of the polymer. The constant alteration of the polymerization and 
depolymerization dynamics of individual and populations of microtubules gives 
microtubules a fundamental and essential role in many cellular processes including cell 
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division, cell structure, and intracellular transport.8 Due to the importance of microtubules 
in cells, particularly in rapidly dividing cells, compounds that bind microtubules, called  
A. 
 
B. 
 
Figure 1.1. Overview of microtubules and MTAs. A. Microtubules are formed when 
dimers of α- and β-tubulin polymerize, forming protofilaments, which cyclize into 
microtubules. B. Overlay of co-crystal structures showing the six known binding sites 
on α- and β-tubulin.  
microtubule targeting agents (MTAs), have long been one of the most important drug 
classes for cancer chemotherapy.8, 9 In addition, these molecules are also approved to treat 
fungal and bacterial infections10, 11 as well as non-neoplastic conditions such as gout12 and 
nonfamilial Mediterranean fever.13 MTAs are currently under investigation for the 
treatment of many neurological disorders.14  
MTAs suppress and alter tubulin dynamics, therefore disrupting dependent cellular 
processes. Treatment with all MTAs results in cell cycle arrest during the late G2/M phase 
at the metaphase/anaphase transition due to inhibiting the separation of sister chromatids 
Taxane 
Site
Laulimalide/
Peloruside Site
Colchicine
Site
Pironetin 
Site
Vinca Site
Maytansine
Site
β-tubulinα-tubulinβ-tubulin
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to the poles, leading to apoptosis.15 There are currently six known MTA binding sites 
identified on tubulin (Figure 1.1B). These efforts have been enabled by the recent advances 
in structural biology, including x-ray crystallography and cryo-electron microscopy, and 
have revealed the finer molecular mechanisms of microtubule targeting agents.16, 17 
The taxane site, bound by paclitaxel, epothilone, and several other ligands, and the 
laulimalide/peloruside site, which are targeted by the named natural products, are known 
as microtubule stabilizing sites. Microtubule stabilizing agents (MSAs) are known to 
promote tubulin assembly or stabilize microtubules by either improving longitudinal 
contacts or by stabilizing lateral connections between protofilaments. MSAs that bind at 
the same site do not necessarily affect stabilization by the same mechanism.18-20 
The other four sites bind ligands known as microtubule destabilizing agents (MDAs) 
and include the vinca, maytansine, colchicine, and pironetin sites. MDAs display diverse 
mechanisms of inhibiting proper microtubule formation, including inhibiting the curved-
to-straight transformation of the tubulin heterodimer, inserting a wedge between assembled 
heterodimers, stabilizing assembly-incompetent polymers, or blocking longitudinal 
interactions.21-23 Unfortunately, the use of terms such as “stabilizers” or “destabilizers” is 
simplistic. The effects of MTAs on microtubule polymer mass 
(stabilization/destabilization) as discussed above is a phenomenon observed at high 
concentrations. Thus, this would only be observed if a patient was maintained at a very 
high dose of MTA. At 10-100× lower concentration, MTAs significantly suppress spindle 
tubulin dynamics. The suppression of dynamics leads to apoptosis by blocking mitosis due 
  
5 
to improperly attached sister chromatids to the spindle microtubules during G2/M phase 
checkpoint.24  
Both types of tubulin inhibitors have been highly effective in the treatment of a variety 
of tumors as individual and combination therapies, but all MTAs approved by the FDA 
bind to β-tubulin. Cancer cells in culture acquire resistance to these drugs through multiple 
mechanisms, including overexpression of multi-drug resistant genes, mutations in β-
tubulin, changes in the tubulin isoform expression, delay of the G2/M transition, defects in 
mitotic checkpoints, and alterations in apoptotic pathways.8, 25 In patients, the best 
documented source of resistance is overexpression of efflux pumps, such as P-glycoprotein 
(P-gp).26-28 Additionally, a connection between tubulin isoform expression and resistance 
has been seen in some cancers.29 It was recently shown that some covalent MTAs can 
counteract and partially overcome drug resistance that is mediated by βIII-tubulin 
overexpression in vitro.30 In contrast, the initial results showing that β-tubulin mutations 
could confer taxol resistance in patients have not been corroborated and is still a subject of 
debate.31, 32 Current anti-tubulin drugs display significant bone marrow toxicity, 
immunosuppression, and neuropathy.33, 34 Thus, there is a critical need to develop novel 
and safer chemotherapeutics, including anti-tubulin therapeutics, that can escape the 
acquired resistance mechanisms and minimize off-target toxicity. Due to the success of β-
tubulin targeting agents, α-tubulin is an attractive alternative therapeutic target, particularly 
in cancers that overexpress P-gp and certain α-tubulin isoforms.35  
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1.3 α-Tubulin Binding Agents 
Each known family of MDAs (vinca alkaloids, maytansines, colchicines, and pironetin) 
interact in some way with α-tubulin, however only the pironetin binding site is exclusively 
located within α-tubulin. The other three binding pockets are located at the interface 
between the tubulin heterodimer and are formed primarily by residues on β-tubulin. The 
growing utility and ease of crystallography has shown that some molecules previously 
thought to bind α-tubulin, namely the hemiasterlin-peptides, actually bind at the interface 
of β-tubulin. The discovery of this information by crystallography means that only the 
natural product pironetin is known to bind exclusively to α-tubulin.  
1.3.1 Pironetin 
Pironetin (1.1, Figure 1.2A) is the only natural product crystallographically 
characterized to bind solely to α-tubulin. Originally known as PA-48153C, this polyketide 
was isolated concurrently from the fermentation broth and cell paste of Streptomyces 
prunicolor36, 37 and Streptomyces sp. NK1095838 bacteria strains. Pironetin was initially 
identified to reduce plant height36 and later identified as a covalent cell cycle regulator.39 
In order to identify the putative binding site, rat 3Y1 cells were treated with a biotinylated-
pironetin derivative labeled as the O7 ester. Subsequent enrichment and pulldown of the 
biotinylated protein-pironetin adduct identified α-tubulin as the protein target. Partial 
digestion of the adduct allowed for a targeted approach to replace lysines and cysteines 
with alanine, leading to the original hypothesis that pironetin undergoes a Michael addition 
with Lys352 of α-tubulin.40 However, two crystallographic studies definitively 
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demonstrate that pironetin binds to Cys316 of α-tubulin by Michael addition (Figure 
1.2B).41, 42 Due to the proximity of Lys352 to Cys316, it is possible that these residues are 
involved in proton transfer, enhancing pironetin binding.  
These results identified a new ligand binding site on tubulin, the first to be exclusively 
within α-tubulin. The binding pocket is not present in the apo structure, indicating that 
pironetin binds through an induced fit mechanism (Figure 1.2C). Pironetin binding opens 
a pocket that is formed by a significant shift in the T7 loop with some residues shifting 
more than 10 Å. In the apo structure, Val250 occupies the space in which the methoxy 
group later sits. When in complex, the T7 loop appears to be stabilized by a salt bridge as 
well as hydrogen bond interactions with both α- and β-tubulin. This could promote 
microtubule disassembly since the interface between the α- and β-tubulin subunits is 
disrupted, preventing longitudinal assembly. 
In addition to the large shift of the T7 loop, the N-terminal end of helix H8, namely 
residues Phe255 and Glu254, re-orient due to the T7 shift. This could further explain the 
mechanism of pironetin’s ability to destabilize microtubule assembly as Glu254 is a key 
catalytic residue. In the apo structure, Glu254 binds to a water molecule that then binds to 
a Mg2+ ion present in the neighboring β-tubulin, which in turn stabilizes GDP.43 When in 
complex with pironetin, Glu254 does not interact with Mg2+ due to the shift. Glu254 is 
thought to significantly enhance the GTPase activity of β-tubulin and, as expected, 
pironetin-treated microtubules display a significant decrease in the GTPase activity.41 
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1.4 Pironetin’s Biological Activity 
Many groups have shown that pironetin displays potent in vitro activity against cell 
lines both sensitive and resistant to current first-line therapeutics (Table 1.1).39, 44-50 
Importantly, pironetin is cancer-cell specific as it was inactive against normal human lung 
fibroblasts (IMR-90), which displayed normal cell-cycle bias and no indications of 
apoptosis following treatment.46 Furthermore, pironetin is not a P-gp substrate.48 
Additionally, in a zebrafish model of blood vessel formation, treatment with pironetin 
Lys352
Cys316
A. B.
Val250
Phe255
Glu254
Val250
Phe255
C.
T7 Loop
H8 Helix
Glu254
Figure 1.2. Pironetin (1.1) covalently binds to α-tubulin by an induced-fit mechanism. 
A. Structure of the natural product pironetin. B. Co-crystal structure of pironetin 
covalently bound to Cys316 of α-tubulin. Lys352 is also highlighted (PDB: 5FNV). C. 
The apo structure is in blue (PDB: 4I55), the pironetin co-crystal structure is in tan 
(PDB: 5FNV). The red arrow shows the movement of the T7 loop upon pironetin 
binding. Glu254, Phe255, and Val250 are highlighted.   
OMe OH O
Et
O
1
5
8
12
Pironetin (1.1)
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resulted in anti-angiogenesis activity.46 Pironetin has been shown to induce apoptosis 
through the intrinsic pathway through B-cell lymphoma 2 (Bcl-2) phosphorylation and 
caspase-3 activation.47 Further, polo-like kinase 1 (Plk1) was found to phosphorylate and 
inactivate Bcl-XL following treatment with pironetin; however, siRNA knockdown of Plk1 
did not suppress pironetin-induced apoptosis, suggesting multiple mechanisms.51 Despite 
the initial characterization of the intrinsic caspase-dependent apoptosis pathway,47, 51 
nothing has yet been reported for pironetin-induced extrinsic apoptosis. 
Table 1.1. Compilation of pironetin’s cellular cytotoxicity  
Abbreviations: GI50, 50% growth inhibitory concentration; PTX, paclitaxel; CP, 
cisplatin; MDR, multi-drug resistant; P-gp, P-glycoprotein. 
 
Cell Line Tumor Type Pironetin 
GI50 (nM) 
Reference 
A2780 Ovarian 24.3 ± 0.9 39, 45, 49 
A2780CP CP resistant A2780 22.3 ± 0.3 49 
A549 Lung 7.5 ± 0.9 46 
DC-3F MDR Chinese Hamster Lung 9.5 ± 1.2 46 
EL4 Thymoma ~15 50 
H69 Lung 17.5 ± 0.9 48 
H69/Tax PTX resistant H69 11.5 ± 0.4 48 
H69/VDS Vindesine resistant H69 20.3 ± 2.3 48 
Hela Cervical ~30 39 
HL-60 Leukemia ~20 47 
K-NRK Murine sarcoma transformed rat kidney ~30 39 
K562 Leukemia 17.3 ± 0.8 48 
K562/ADM MDR/P-gp overexpressing K562 16.0 ± 1.3 48 
MCF-7 Breast 5.0 ± 0.2 46 
MDA-
MB231 
Breast 4.6 ± 1.2 46 
OVCAR5 Ovarian 14.4 ± 0.8 44, 45 
P388 Mouse Leukemia ~100 47 
T98G Glioma 7.5 ± 1.2 46 
VCRd5L MDR Chinese Hamster Lung 31.0 ± 5.0 46 
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Despite pironetin’s potent in vitro activity, only two in vivo studies have been reported 
in literature.39, 50 Towards demonstrating pironetin’s immunosuppressant activity, mice 
bearing EL4 thymoma cells were treated with intraperitoneal (IP) pironetin injection (Table 
1.2). After 16 days, the mice were sacrificed and the spleen was harvested to create effector 
cells, which were utilized to understand pironetin’s effect on the generation of cytotoxic T 
cells. Pironetin significantly suppressed the generation of cytotoxic T cells as compared to 
vehicle treatment at a 5 mg/kg dose, indicating that pironetin has potent 
immunosuppressant activity.50 While no positive control was reported in vivo, 
cyclosporine was run in the preliminary in vitro assay and showed a 4- and 800-fold loss 
in IC50 as compared to pironetin against concanavalin A-stimulated T cell and 
lipopolysaccharide-stimulated B cell proliferation, respectively.  
Table 1.2. Effect of pironetin on the generation of cytotoxic T cells in EL4 bearing mice50 
Compound Dose 
% Specific Lysis 
(Effector/Target Cells=50) 
Control 0 mg/kg 18.6 ± 4.1 
Pironetin 5 mg/kg 7.4 ± 2.2 
In the second in vivo study, pironetin was monitored for its antitumor activity (Table 
1.3). Pironetin was injected IP daily for five days (day 1 through day 5) into mice bearing 
P388 murine leukemia cells. Mortality was monitored and the mice were weighed on days 
1 and 10. At relatively high doses as compared with other microtubule targeting agents, 
pironetin led to a very modest improvement in mean survival time, however this was 
accompanied by significant weight loss.39 Together, these in vivo studies demonstrate that 
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pironetin was only moderately effective in reduction of P388 tumor burden, caused 
significant weight loss, and was highly immunosuppressant.  
Table 1.3. Antitumor activity of pironetin in P388 bearing mice39 
Compound Dose 
Body Weight 
Change (g) 
Mean Survival 
Time (days) 
Control 0 mg/kg 5.3 11.2 ± 0.8 
Pironetin 0.78 mg/kg 3.7 11.2 ± 0.6 
 1.56 mg/kg 0.5 11.7 ± 0.6 
 3.13 mg/kg -0.1 13.3 ± 1.2 
 6.25 mg/kg -2.6 14.3 ± 0.6 
The minimal antitumor activity could be explained by pironetin’s decreased 
cytotoxicity against P388 cultured cells as compared to other tumor cell lines and by the 
observation that >500 nM pironetin was required to induce apoptosis in cultured P388 
cells.47 It is probable that the optimal tumor type to demonstrate pironetin’s activity was 
not used. Alternatively, pironetin could display poor pharmacokinetic/pharmacodynamic 
(PK/PD) properties or off-target binding, limiting the amount of cytotoxic agent that 
reaches the site of the tumor. While an extensive amount of work has been published 
highlighting these synthetic efforts, no pironetin analogs have yet been evaluated in vivo 
for cytotoxicity. 
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Figure 1.3. Summary of published pironetin total syntheses sorted into type of strategy: 
convergent, iterative aldols and pseudo-aldols, pentenylation, allylation, and crotylation, 
and other. 
1.4 Total Syntheses of Pironetin 
At the time of submission of this dissertation, 12 distinctive total syntheses of pironetin 
have been published, highlighting the synthetic and biological intrigue of this natural 
product. These syntheses have enabled the study of pironetin and its analogs and are 
summarized in Figure 1.3. They are divided into several classes: iterative aldol and pseudo-
aldol condensations (blue), convergent syntheses (red), iterative pentenylation or 
crotylation (yellow), and other (green). While the authors have attempted to classify the 
syntheses in a simple manner, many of the syntheses do not conform to a single class and 
are placed where the most novel chemistry was developed.  
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The first total synthesis of pironetin was reported by Kawada and coworkers in 1995 
and employed a convergent route starting from (S)-Roche ester and a substituted α-D-
glucopyranoside.52 In 13 and 8 steps, respectively, the ester was converted to 
polypropionate fragment 1.3 and the pyranoside was converted to aldehyde 1.2, which were 
then coupled under Wittig conditions. An additional 13 steps were required for installation 
of the unconjugated olefin and generation of the unsaturated lactone, a total of 34 steps. 
This total synthesis established the absolute configuration of the natural product. 
In 1996, Rao and coworkers reported their first total synthesis of pironetin which relied 
upon iterative olefination, generating intermediate allylic alcohol 1.4, followed by a highly 
diastereoselective Sharpless epoxidation to yield epoxide 1.5. The linear synthesis was 
initiated from diethyl methylmalonate and required 35 total steps.53, 54 Improving upon their 
first synthesis, Rao and coworkers published a second linear total synthesis in 1997, the 
only non-convergent one to date which builds the molecule out from an established lactone 
core at an early stage. This synthesis began from propargylic alcohol and relied on a key 
Grignard addition to epoxide 1.6, leading to 1.7. The remaining syn stereochemistries were 
installed via an Evans aldol and a regiospecific reductive opening of a tertiary epoxide, 
yielding pironetin in 33 overall steps.55  
In 1997, Chida and coworkers reported the convergent synthesis of pironetin from L-
quebrachitol to set four consecutive chiral centers of the polyketide core 1.8 in 14 steps 
and L-malic acid to form alkene 1.9 in 9 steps. These intermediates were coupled and 
following functional group manipulation, pironetin was completed in 28 total steps.56  
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The final convergent synthesis of pironetin was reported in full by Kitahara and 
coworkers in 199857 and the route was utilized again in 1999 to generate demethylpironetin 
and other analogs, but these were not evaluated for biological activity.58 Using chiral 
building block 1.10 (9 steps to synthesize), intermediate 1.11 was obtained in 13 steps, 
which was coupled with epoxide 1.12. Compound 1.12 was synthesized from propargylic 
alcohol in 14 steps through addition of propargyl ether followed by hydrogenation, 
protecting group exchanges, and epoxidation. Coupling of 1.11 and 1.12 was followed by 
additional manipulation of the skeleton into pironetin, a total of 28 steps.   
Keck’s 2001 total synthesis applied three new methodologies developed by his group. 
Many other groups would continue to use these methods in pironetin total syntheses and 
analog development. Starting from (S)-Roche ester, aldehyde 1.13 was synthesized in 11 
steps utilizing a diastereoselective crotylstannane addition59 followed by conversion to the 
trans-olefin. Aldehyde 1.13 then underwent a Mukiyama aldol condensation with silyl enol 
ether 1.14 (generated in 5 steps), followed by the reduction of a β-hydroxy ketone to the 
anti-1,3-diol using samarium iodide,60 and finished with a lactone annulation series,61 a 
total of 17 steps.62  
Following Keck’s synthesis, a number of groups began on iterative aldol and pseudo-
aldol condensations to generate the pironetin backbone. In 2003, Dias published the total 
synthesis highlighting iterative Evans’ oxazolidinone mediated syn-aldol condensations to 
build out the backbone. This synthesis commenced from 1,3-propane diol and the 
condensations started with aldehyde 1.15 to grow out to intermediate 1.16, which was 
converted into pironetin after additional steps.63 Of note is the first use of a Z selective 
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olefination as the penultimate step.64 Dias’s synthesis of pironetin required 21 total steps, 
not including auxiliary synthesis.  
One of the disadvantages of Evans’ auxiliaries is the cleavage. In 2000 Crimmins 
disclosed the use of thiazolidinethione auxiliaries, which are easily cleavable directly to 
the aldehyde and other functional groups.65 In 2009, Crimmins and coworkers reported the 
total synthesis of pironetin using this strategy starting from alkene 17 through intermediate 
1.18 in 11 steps, including the penultimate Z olefination.64 Synthesis of 1.17 requires four 
additional steps, for a total of 15 steps.66 
In an effort to apply catalytic asymmetric aldols to pironetin’s total synthesis, Nelson 
and coworkers developed acyl halide-aldehyde cyclocondensations (AACs) which 
generate enantioenriched β-lactones as propionate aldol units.67 The total synthesis 
utilizing this approach was reported in 2006. Starting from 1,3-propane diol, aldehyde 1.19 
was synthesized and underwent iterative AACs to generate intermediate 1.20, followed by 
acylation, and lactonization to generate pironetin in 15 linear steps.68 
The final iterative pseudo-aldol approach was published by Enders and coworkers in 
2007 and employed the SAMP/RAMP hydrazone methodology that he developed 
throughout his career. Beginning from butanone, an asymmetric aldol with the SAMP 
hydrazone and subsequent trapping with 3-(benzyloxy)propanal generated hydrazone 1.21, 
which was converted to aldehyde 1.23 in 5 steps. Silyl enol ether 1.22 was prepared from 
3-pentanone in 5 steps. Mukiyama aldol condensation between 1.22 and 1.23 provided the 
β-hydroxyketone, which was converted to pironetin in a similar manner to Keck’s total 
synthesis,62 taking 17 total steps.69  
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In 2008, Cossy and coworkers published the total synthesis of pironetin by disclosing 
two methodologies developed in house. The synthesis began from (S)-Roche ester and 
underwent an enantio- and diastereoselective titanium mediated crotylation followed by an 
allylation with a similar complex to generate tosylate 1.24. After tosyl displacement with 
propyne and methylation, the terminal olefin was oxidatively cleaved and subjected to a 
boron-mediated pentenylation, generating homoallylic alcohol 1.25. The synthesis was 
completed through a one-pot hydrosilylation/ring-closing metathesis/protodesilylation, a 
total of 14 steps and the shortest synthesis of pironetin to date.70  
The most recent total synthesis was reported in 2010 by Yadav’s group and relied on 
iterative Prins cyclizations followed by reductive cleavage. Prins cyclization between an 
(S)-Roche ester-derived aldehyde and a diol generated tetrahydropyran 1.26. Installation 
of the unconjugated olefin via functional group manipulation led to homoallylic alcohol 
1.27, which then underwent a second Prins cyclization. Pironetin was obtained following 
reductive opening, transformation to an acrylate, and ring-closing metathesis in 28 total 
steps.71  
In addition to the total syntheses discussed above, a key fragment towards pironetin’s 
synthesis has been synthesized (Figure 1.4), however the completed route has not been 
published.72 Starting from a modified D-glucal (1.28), Ferrier rearrangement afforded the 
O-glycoside, which underwent protecting group exchange and Grignard addition to install 
pironetin’s C4 ethyl substituent. Conversion to ketone intermediate 1.29 was achieved by 
a one carbon homologation using sodium cyanide followed by conversion to the aldehyde, 
a Grignard addition, and final oxidation. Synthesis of ketone 1.29 was completed in 11 
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steps. The Sarabia group envisioned completion of the total synthesis in a convergent 
manner through an aldol condensation with the remaining western fragment of pironetin 
followed by reveal of the lactone, however this has not yet been reported.  
 
Figure 1.4. Chiron approach to the lactone fragment 1.29 by Sarabia and coworkers. 
In all, many of the 12 total syntheses published highlight the utility of novel or new 
methodology. While this exceedingly short discussion does not do any of the chemistry 
justice, it becomes obvious that despite the small size of pironetin, this natural product is 
challenging to prepare and will hopefully continue to inspire chemists to invent new 
chemistry for its synthesis. Furthermore, the total syntheses discussed above have 
facilitated much of the discovery and development of fully elucidated pironetin analogs in 
order to explore the structure activity relationship (SAR).  
1.5 Development of Pironetin’s Structure-Activity Relationship 
1.5.1 Early Studies – Isolated and Semi-Synthetic Analogs 
Soon after pironetin’s isolation from the Streptomyces prunicolor36, 37 and 
Streptomyces sp. NK1095838 bacteria strains, several additional derivatives were isolated 
from these same strains and semisynthesis led to a handful of others (Figure 1.5). Of note, 
demethylpironetin (1.29) and 2,3-dihydropironetin (1.32) were isolated from bacteria,73 
and epoxypironetin (1.34) was synthesized from pironetin.39 These analogs were shown to 
be equipotent, 1000×, and 25× less potent than pironetin, respectively, in cell cycle arrest 
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assays, while tetrahydropironetin (1.33) lost 2000× activity.73 A total synthesis of 3-
hydroxy pironetin (1.30) and (+)-pironetin (1.35) revealed a 75× loss and a complete loss 
(10,000×) of activity, respectively.46 Finally, total synthesis of epi-C7 pironetin (1.31) and 
C7 oxidation to generate ketone 1.28 led to 1000× and 100× loss of activity, respectively, 
as compared to pironetin.73 
A number of O7 ethers, esters, carbonates, and carbamates have been synthesized from 
pironetin (Figure 1.4).50 Each of these analogs lost activity as compared to pironetin. 
Notably, methyl ether 1.36 was 10× less potent; however installation and elongation of 
esters (series 1.37) with alkyl chains showed that the activity could be mostly recovered in 
a few instances.73 Conversion to carbonates (series 1.38) or carbamate reduced activity by 
30-80× over pironetin. The four O7 series of analogs were also evaluated for 
immunosuppressant activity. It was discovered that each of these analogs were potent in 
vitro immunosuppressants that inhibited the proliferative response of mouse spleen cells in  
 
Figure 1.5. Early SAR exploration of pironetin (a. M phase arrest and microtubule 
disassembly;73 b. MCF-7 cells;46 c. M phase arrest;39 d. EL4 cells50).   
1.1 R1 = Me; R2 ((-)-Pironetin)
1.28 R1 = Me; R2 =  C=O  (100x)a
1.29 R1, R2 = H (Demethylpironetin, 1x)a
OMe OH O
Et
O
1.32 (1000x)a
OR1 OR2 O
Et
O
1
5
8
12
OMe OH O
Et
O
1.33 (2000x)a
OMe OH O
Et
O
1.35 (+)-Pironetin (10,000x)b
OMe OH O
Et
O
1.34 Epoxypironetin (25x)c
O
OMe OR1 O
Et
O
1.36 R1 = Me (10x)d
1.37 R1 = COR (21 compounds, 3-100x)a & d
1.38 R1 = COOR (R = Bu, Ph, 30x)d
1.39 R1 = CONHCOPh (80x)d
OMe OH O
Et
O
OH
1.30 (75x)b
OMe OH O
Et
O
1.31 epi-C7 Pironetin (1000x)
a
  
19 
response to both T cell and B cell mitogens. The analog activities were comparable to 
pironetin’s immunosuppressant activity (1-10× less active).50 
1.5.2 Simplified Pironetin Analogs 
Due to the complex syntheses required to generate pironetin analogs, several simplified 
pironetin series have been prepared and are summarized in Figure 1.6. Despite the 
simplified nature, these analogs still required at least eight steps to synthesize. The eight 
diastereomers making up Series I and the four of Series II were synthesized and both series 
of molecules showed a significant loss in cytotoxicity as compared to pironetin (µM vs 
nM) in the A2780 cell line.74 The four pyrones in Series III and IV explored the necessity  
 
Figure 1.6. Simplified pironetin analogs. (a. A2780 cells;74 b. A2780 cells;75 c. MCF-7 
cells76). 
of the alkyl substituents along the polyketide backbone and again these analogs showed a 
significant loss of cytotoxicity in the A2780 cell line.75 Finally, the last three series, V,75 
VI,76 and VII,76 evaluated the size of the lactone ring and substitution at the C4 position, 
demonstrating the importance of the δ-lactone for cytotoxicity.  
Taken together, these series demonstrate the importance of all alkyl pendants and the 
size of the lactone. Additionally, the presence of the C4 ethyl substituent in the R 
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configuration seems to significantly improve activity, as is evident when comparing series 
I and V, and an anti-relationship between the C5 and C7 substituents appears to be slightly 
preferred. The importance of the relative and absolute configuration between C5, C7, and 
C9 remains ambiguous as no clear preference was observed. Despite the loss in cytotoxicity 
as compared to pironetin, treatment with each series of compounds caused accumulation 
of cells in the G2/M phase and disrupted the microtubule network in a similar manner to 
pironetin, albeit at much higher concentrations than pironetin. This is important as it 
suggests that these simplified analogs interact with tubulin with the same general 
mechanism as pironetin.74  
1.5.3 Fully Elucidated Analogs Through Total Synthesis 
The lessons learned from the simplified pironetin SAR campaign showed that all alkyl 
pendants along the polyketide backbone seem necessary for high activity, highlighting the 
need for an extended study of fully elucidated pironetin analogs. Since pironetin covalently 
modifies α-tubulin through the unsaturated lactone41, 42 and an in vivo study reported 
significant weight loss,39 the possibility of off-target effects through a covalent mechanism 
is likely, prompting an extensive SAR at the C2, C4, and C5 positions through total 
synthesis. These series are shown in Figure 1.7 and were evaluated for cytotoxicity against 
A2780, OVCAR5, or EL4 cell lines.  
The C2 series was aimed at generating reversible covalent modification of α-tubulin45 
to reduce off-target reactivity by incorporating electron-deficient groups.77, 78 Analogs 
1.40-1.43 demonstrated that alteration of the C2 site abolished activity, with only the α-
bromo analog 1.44, retaining some activity. The C4/C5 series investigated the importance 
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of the lactone configuration44 and determined that, unlike previous studies with simplified 
analogs by Marco and coworkers,74-76 modification of the C5 configuration is not well 
tolerated, as is evident by the reduced activity of analogs 1.45 through 1.47. The C4 analogs 
(1.48-1.57) probed the effects of epimerization, incorporation of larger and smaller 
substituents, and disubstitution. The results for this series suggested that a single 
substituent at C4 with the same configuration as the natural product is required. Some small 
alkyl C4 analogs were well tolerated, including cyclopropyl (1.53) and n-propyl (1.51), 
however bulkier groups, such as benzyl (1.55) and iso-propyl (1.56) resulted in substantial 
loss of activity.  
 
Figure 1.7. Pironetin analogs exploring C2, C4, and C5 through total synthesis and C13 
through semisynthesis. (a. A2780 cells; 45 b. OVCAR5 cells;44 c. EL4 cells50). 
Finally, a small C13 series was generated in which the unconjugated olefin was 
converted to the 14,14-dimethyl (1.58) and the 14,14-dibromo (1.59) analogs. This was 
accomplished through ozonolysis of pironetin followed by olefination of the resulting 
aldehyde.50 Both analogs were about equipotent to pironetin, suggesting that further 
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22 
exploration of this olefin could be the key to improving the properties of this molecule 
towards future drug development. 
1.5.4 Lessons from Structural Biology 
Following the release of the co-crystal structures of pironetin with α-tubulin, much of 
the reported SAR can be explained and rationalized (Figure 1.8). The C4 ethyl substituent 
binds in a narrow hydrophobic pocket and contacts Leu378. Inclusion of a smaller group, 
such as methyl, reduces this hydrophobic interaction, while inclusion of a bulkier group, 
such as isopropyl, cannot be accommodated in this small hydrophobic pocket. Further, 
altering the configuration at C4 or C5, or including two substituents at C4 would alter the 
ring conformation. The removal of the alkyl side chains along the polyketide backbone 
may alter the preferred conformation of the pironetin analogs. In addition, the lactone of 
pironetin is positioned near a β-sheet, at a distance of 4.7 Å, which indicates why the 
introduction of C2 substituents could not be tolerated. Finally, the most successful analogs 
have been the C13 series, which take advantage of a small pocket of available space flanked 
by hydrophobic residues and Cys4. Despite the extensive SAR around pironetin, no 
analogs have been co-crystallized with tubulin.  
1.6 Future Directions and Questions of Interest 
The development of new microtubule targeting agents remains of quintessential 
importance, particularly the discovery and development of agents with novel interactions 
with microtubules. Many questions remain, some of which were recently highlighted,16 
however many other ideas require attention, including studying how microtubule 
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Figure 1.8. Insight into pironetin’s SAR (PDB: 5FNV). A. Pironetin’s lactone is placed 
against a β-sheet strand. The C4 ethyl substituent fills a hydrophobic pocket, favorably 
contacting Leu378. B. Pironetin’s polyketide backbone ends in a partially open pocket 
framed by Cys4 and Leu137. The alkyl pendants do not appear to make direct interactions 
but could aid in pironetin’s assembly into the proper conformation for binding. 
targeting agents impact the interaction of microtubules and microtubule associated 
proteins. Understanding the disparity between β-tubulin and α-tubulin targeting molecules 
is of interest and could be aided by developing methodology in which to better study and 
characterize MTA interactions with microtubules in cellular, biophysical, and biochemical 
assays. Particularly with the improvements in structural biology and screening 
technologies, discovery of natural product and non-natural product-like molecules that 
bind α-tubulin should be possible.  
In addition to discovering new α-tubulin targeting scaffolds, further development of the 
pironetin SAR is key. Due to the difficulty in synthesizing analogs, there remains a 
significant gap in knowledge, and of utmost importance is the development of pironetin 
analogs that show improved PK/PD properties, generating at least tool compounds that 
would allow in vivo evaluation of an α-tubulin targeting agent. Further, development of 
non-covalent or targeted α-tubulin specific agents is critical as this would likely reduce off-
target binding and increase the utility and safety profile significantly. Despite the reported 
Leu378
Cys4
Leu137
A. B.
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crystal structures, the complexity of pironetin’s binding mode (covalent and induced fit) 
substantially complicate and limit computational methods which should be used to discover 
additional scaffolds or design analogs. Using protein-based methods, for example, docking, 
even using CovDock, is oversimplified and does not correlate with activity data.44 Using 
ligand-based methods, such as QSAR or pharmacophore modeling, could provide more 
accurate predictions for driving the development of pironetin and other pironetin-site 
binding molecules. 
Finally, the importance and utility of targeting α-tubulin instead of (or in combination 
with) β-tubulin is entirely unknown territory. Pironetin’s binding site is separate from all 
approved β-tubulin targeting molecules, explaining why pironetin is active in cells that 
have become resistant to β-tubulin targeting drugs. Interestingly, a pironetin-resistant cell 
line has not been disclosed. This indicates that pironetin or α-tubulin binders could be 
useful probes to understand β-tubulin resistant cancers and show great utility against 
tumors that have become resistant to first line tubulin-binding chemotherapeutics. 
  
  
25 
Chapter 2: Identification of Pironetin’s Metabolic Liabilities 
*Adapted from Coulup, S.K. et al. J. Med. Chem. 2019, 62, 1684-1689. 
2.1 Introduction 
All microtubule inhibitors currently approved by the FDA bind to β-tubulin, and the 
development of an agent that binds instead to α-tubulin has the potential to be active in 
cancers resistant to taxanes and other microtubule inhibitors which target β-tubulin. Given 
the overall success of β-tubulin-binding anticancer agents in cancer chemotherapy, α-
tubulin is an attractive target. In addition, it was recently shown that the gene encoding α-
tubulin isoform TUBA3C is overexpressed in ovarian cancers and is associated with 
increased resistance to first-line chemotherapeutics and shorter survival time.35 Pironetin 
(1.1, Figure 2.1A) is the only natural product structurally characterized by x-ray 
crystallography to bind α-tubulin. Pironetin covalently binds to Cys316 of α-tubulin 
(Figure 2.1B).40, 41  
 
Figure 2.1. Structure and binding mode of pironetin. A. Pironetin (1.1) is an α,-
unsaturated lactone which (B.) covalently binds with Cys316 of α-tubulin in a 1,4-
conjugate addition.  
Due to pironetin’s unique properties, several groups have recently reported the 
synthesis and in vitro evaluation of pironetin analogs, including structurally simplified 
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analogs.44, 45, 74, 75, 79 While pironetin has promising in vitro activity, the causes of the poor 
in vivo activity need to be identified and addressed in order to arrive at a lead compound. 
To address these issues, we report the identification of pironetin’s major metabolites in 
human liver microsomes (HLM) using mass spectrometry and semisynthesis.  
 
2.2 Preliminary In Vitro PK Evaluation 
In an effort to explain pironetin’s poor in vivo efficacy, we first characterized the in 
vitro PK profile of pironetin (Table 2.1). Pironetin displays a short serum half-life in 
human, mouse, and rat preparations (performed by Dr. David Huang) and a short half-life 
in each species of liver microsomes. These data suggest that a key reason for the marginal 
in vivo activity could be rapid metabolism.  
Table 2.1. In vitro PK properties of pironetin 
 Human Mouse Rat 
Serum Stability (%)b 50 35 56 
Metabolic t1/2 (min)a 7 <15c <15c 
% Protein Bounda 87 98 93 
 
a Performed by Eurofins-CEREP 
b % Remaining after 24 h 
c Undetected after 15 min 
In addition to serum and microsomal half-life, we submitted pironetin for P450 inhibition 
studies to evaluate the potential for drug-drug interactions against Cyp2C9, 2D6, and 3A4 
and found pironetin slightly inhibits metabolism of midazolam and testosterone by 
Cyp3A4 but not at relevant concentrations based on pironetin’s cytotoxicity in vitro (Table 
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2.2). Pironetin does not significantly inhibit metabolism of tolbutamide (by 2C9) or 
dextromethorphan (by 2D6) but has a small effect on the metabolism of midazolam or 
testosterone (both by 3A4).  
Table 2.2. Inhibition of P450 isoforms by pironetin 
 IC50 (μM)a 
 2C9 2D6 3A4-
Midazolam 
3A4-
Testosterone 
Sulfaphenazole 0.54 - - - 
Quinidine - 0.11 - - 
Ketoconazole - - 0.018 0.30 
Pironetin >50 >50 28.99 37.79 
 
a Performed by Pharmaron 
2.3 Identification of Metabolic Soft Spots in HLM 
Identification of metabolic soft spots can aid in lead design and also minimize potential 
safety concerns, such as the formation of reactive or toxic metabolites80, 81 or drug-drug 
interactions.82 Liquid chromatography-mass spectrometry (LC-MS) is a leading method 
for metabolite identification.83-86  
 
Figure 2.2. SMARTCyp predicted sites of pironetin metabolism. The top three predicted 
sites for the Cyp3A class are circled. Sites with a score of <70 are indicated with a star. 
Pironetin’s sites of metabolism were predicted using the SMARTCyp software prior to 
performing experiments.87 SMARTCyp is a 2D method primarily used to predict P450-
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mediated metabolites from the Cyp3A, 2D, and 2C classes. Sites are scored based on 
fragment matching reactivity, accessibility of the site of metabolism to the heme core of 
the cytochrome P450’s, and solvent accessible surface area with the lowest score being the 
most likely site of metabolism. When pironetin was evaluated by SMARTCyp, nearly 
every carbon along the pironetin backbone held reasonably low scores (score of 70 or less, 
Figure 2.2 red stars), while the remaining sites, C5 and C10, had scores less than two above 
the cut off. The C8 methyl groups and C10 were scored between 10 and 12 above the cut 
off. The score cut off was determined based on known metabolites of current therapeutics. 
This prediction suggests that pironetin is labile to P450-mediated oxidation, further 
strengthening our hypothesis that pironetin’s utility could be significantly limited by rapid 
metabolism.  
To identify the sites of metabolism, pironetin was incubated with HLM and a NADPH 
regeneration system for up to an hour. The resulting samples were analyzed by LC-MS on 
a Thermo Orbitrap Velos using atmospheric pressure chemical ionization (APCI). LC-MS 
revealed that pironetin has two major metabolites, M2 and M4, and at least three minor 
metabolites, M1, M3, and M5 (Figure 2.3A). Analysis of the MS spectrum of pironetin 
(Figure 2.3B) and the major metabolite M4 (Figure 2.3E) revealed a single oxidation site 
near the unconjugated olefin. The MS spectrum of M2 (Figure 2.3D) suggests secondary 
oxidation of M2 predicted to occur around the lower half of the lactone or along the 
backbone closest to the lactone. Metabolites M1 and M3 are predicted to be isomers of the 
pironetin ketone which has also been oxidized along the eastern most backbone (Figure 
2.3C) and the minor metabolite M5 is formed by a demethylation (Figure 2.3F). Based on 
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the importance of M4, we next sought to confirm the structure of this major metabolite 
through semisynthesis of epoxypironetin (M4). Further, as demethylpironetin (M5) has 
previously been isolated from pironetin-producing bacteria strains, we wished to confirm 
demethylpironetin as a minor metabolite.88  
 
Figure 2.3. Pironetin has two major metabolites (M2 and M4) and three minor metabolites 
(M1/M3 and M5). A. LC trace of human liver microsome sample showing pironetin and 
its five metabolites formed after a 30 min incubation. MS traces of B. pironetin; C. M1/M3; 
D. M2; E. M4; and F. M5 with fragmentation patterns and the predicted locations of 
metabolism highlighted.  
  
30 
2.4 Semisynthesis of Epoxypironetin and Demethylpironetin 
Since the primary pironetin metabolite (M4) showed oxidation around the non-
conjugated olefin, we hypothesized this could correspond to either epoxidation of the olefin  
or oxidation at one allylic position. An authentic sample of the predicted metabolite 
epoxypironetin was synthesized from pironetin as shown in Scheme 2.1. Pironetin was 
obtained from the fermentation broth of Streptomyces prunicolor as previously 
described,36, 37 and was then treated with mCPBA to afford epoxypironetin. Efforts towards 
allylic oxidation of the model substrate using selenium dioxide were unsuccessful, and due 
to the limited amount of pironetin available, Riley oxidation of pironetin was not attempted. 
In addition to epoxypironetin, demethylpironetin is a natural product which has also been 
isolated from pironetin producing Streptomyces strains.88 Since M5 from the metabolite 
Scheme 2.1. Synthesis of epoxypironetin (M4) and demethylpironetin (M5) 
 
identification studies suggested demethylation as a minor metabolic pathway, we 
hypothesized this metabolite could correspond to demethylpironetin. An authentic sample 
of demethylpironetin was synthesized from pironetin with BBr3 as shown in Scheme 2.1.89  
To evaluate whether epoxypironetin or demethylpironetin were metabolites M4 and M5, 
respectively, we obtained LC-MS traces of both potential metabolites and determined that 
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the retention time (Figure 2.4) and fragmentation pattern (Figure 2.5) of the major pironetin 
metabolite produced by HLM (M4) matched the epoxypironetin trace. Demethylpironetin 
was present (d) but in trace amounts as compared to epoxypironetin. Together, these data 
suggest that epoxypironetin is a major metabolite in HLM while demethylation is not a 
significant metabolic liability. As epoxypironetin matched the major metabolite, further 
efforts towards synthesizing pironetin allylic alcohols were not pursued. 
 
Figure 2.4. LC traces of human liver microsome reaction (top) compared to the synthesized 
epoxypironetin (M4, middle) and demethylpironetin (M5, bottom) standards. 
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2.5 Biological Evaluation  
We determined the antiproliferative activity of pironetin, demethylpironetin, and 
epoxypironetin against chemotherapeutic sensitive and resistant ovarian cancer cell lines 
(Table 2.3).90 Epoxypironetin was previously synthesized from pironetin and 
demethylpironetin was previously isolated from pironetin producing bacteria strains.39,91 
These derivatives were shown to be approximately 25-fold less effective and equipotent, 
respectively, than pironetin in arresting 3Y1 rat fibroblast cells at the G2/M phase.39 
Additionally, epoxypironetin was found to have a minimum inhibitory concentration 
against A2780 sensitive ovarian cancer cells of 540 nM (as compared to pironetin’s 26 
nM).91   
Table 2.3. In vitro cytotoxicity evaluation of pironetin, epoxypironetin, and 
demethylpironetin 
 GI50 (nM)a 
 A2780b A2780CPc 
Pironetin (1.1) 22.2  1.0 22.3  3.0 
Epoxypironetin (M4) 218.2  1.8 1014.9  1.3 
Demethylpironetin (M5) 29.6  1.4 82.3  1.9 
 
a Each measurement is in triplicate on a minimum of two 
separate experiments 
b Drug-sensitive ovarian cancer cell line 
c Cisplatin-resistant ovarian cancer A2780 cell line 
A2780 is a sensitive ovarian cancer cell line that was harvested from the tumor tissue 
of an untreated patient.92 A2780CP was derived from chronic exposure of the sensitive 
A2780 strain to cisplatin, rendering this strain resistant to cisplatin treatment.93 Our data is 
consistent with previous reports and confirms that pironetin and demethylpironetin display 
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similar cytotoxicity against the A2780 sensitive ovarian cancer cell line, while 
epoxypironetin is approximately 20-fold less cytotoxic than pironetin. Additionally, our 
data shows that both demethylpironetin and epoxypironetin are four times and 46-fold less 
cytotoxic than pironetin in A2780CP cells, respectively. 
2.6 Discussion and Conclusion 
Our data establishes that pironetin is rapidly and extensively metabolized, primarily to 
epoxypironetin, which displays significantly reduced cytotoxicity. It is probable that the 
epoxide has a short half-life in vivo due to its high electrophilicity. The liver contains a 
high concentration of nucleophilic glutathione (GSH) (~7 mM) as well as microsomal and 
soluble epoxide hydrolases (EH), which catalyze the hydration of epoxides to form the 
diol. Neither GSH or EH were present in the human liver microsome preparations utilized 
here, however both reactions are common detoxicification methods which could further 
explain the marginal in vivo efficacy.94, 95  
In summary of this chapter, we have shown that the natural product pironetin is rapidly 
metabolized to several metabolites in human liver microsomes. We identified the major 
site of metabolism of the natural product pironetin to be the unconjugated olefin, as well 
as found several minor labile sites along the backbone. Further investigation revealed the 
major metabolite to be epoxypironetin (M4), which was confirmed when the synthesized 
epoxypironetin standard matched the retention time and fragmentation pattern of the major 
metabolite formed. Epoxypironetin loses between 20- and 50-fold activity against the two 
ovarian cancer cell lines tested. Epoxypironetin is further oxidized along the eastern portion 
of the molecule to generate the second major metabolite. Additionally, two minor, isomeric 
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metabolites are formed by the dual oxidation of the eastern portion, and the demethylation 
of C9 leads to the minor metabolite demethylpironetin (M5), as determined by 
semisynthesis.  
These results were partially predicted by the use of the SMARTCyp software, which 
predicted metabolism along most of the aliphatic backbone. Pironetin was also shown to 
slightly inhibit metabolism of midazolam and testosterone, both metabolized by Cyp3A4. 
As pironetin has nM cytotoxicity and is rapidly metabolized, it is unlikely that the 
concentration of pironetin will ever be high enough to affect drug metabolism through 
Cyp3A4. These data show that pironetin has several major metabolic liabilities which need 
to be addressed in order for a lead molecule to emerge. Further, our work provides an 
explanation for the marginal in vivo efficacy of pironetin. In summary, we have shown that 
the natural product pironetin is rapidly metabolized to several metabolites. We identified 
the major site of metabolism of the natural product pironetin to be the unconjugated olefin 
in human liver microsomes, as well as found several labile sites along the backbone. 
Further investigation suggests the major metabolite in HLM to be epoxypironetin (M4), 
which was independently synthesized and found to have matching retention time and 
fragmentation pattern to the major pironetin metabolite formed in both microsomal 
preparations.   
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Chapter 3: Total Synthesis and Evaluation of a Metabolically 
Stabilized Pironetin Analog 
 
3.1 Introduction 
     We have shown that pironetin is rapidly metabolized by human liver microsomes 
(HLMs) to epoxypironetin (M4) and several additional metabolites with reduced potency 
and the presumed ability to be detoxified or form adducts.49 We therefore were interested 
in determining if blocking the unconjugated olefin site of metabolism would improve the 
metabolic stability while maintaining potency. In addition, we and others have reported 
that demethylpironetin, a natural product isolated from pironetin producing bacteria strains, 
has similar potency to pironetin against sensitive and resistant ovarian cancer cell lines. 
We were therefore interested in developing the first synthetic route towards demethylated 
analogs. To begin to address the first hypothesis, Dr. David Huang first synthesized  
 
 Phenylpironetin 
GI50 (OVCAR5a) 57 nM 
GI50 (A2780a) 68 nM 
Liver Microsome Half-Life (Human)b 5 min 
Liver Microsome Half-Life (Mouse)b 4 min 
 
a Drug-sensitive ovarian cancer cell line. 
b Performed by CEREP. 
 
Figure 3.1. Cytotoxicity and metabolism evaluation of phenylpironetin (3.1) in cells and 
liver microsomes. Synthesis and cellular evaluation performed by Dr. Huang.  
OMe OH O
O
Et
Phenylpironetin (3.1)
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phenylpironetin (3.1) and evaluated it against sensitive ovarian cancer cells lines and for 
metabolic half-life in human and mouse liver microsomes (Figure 3.1, unpublished data). 
Dr. Huang showed that while cytotoxicity was maintained, the metabolism was not 
improved over pironetin. To continue analog exploration towards improved metabolic 
stability while also developing the first route towards demethylated pironetin analogs, we 
sought to synthesize 4-fluorophenyldemethylpironetin. We report here efforts towards the 
total synthesis and biological evaluation of 4-fluorophenyldemethylpironetin (3.2, Figure 
3.2) in which the unconjugated olefin has been replaced to improve metabolic stability.  
 
Figure 3.2. Structure of target molecule 4-fluorophenyldemethylpironetin. 
3.2 Synthesis of 4-Fluorophenyldemethylpironetin (3.2) 
3.2.1 Route Design 
At the time of initiation of this synthesis, no route towards demethylated pironetin 
derivatives had been published. To address this, we initially embarked on the total synthesis 
utilizing similar chemistry and disconnects adapted from the phenylpironetin (3.1) 
synthesis. However, during our exploration towards synthesizing 4-fluorophenylpironetin, 
it became evident that the presence of fluorine significantly hindered several stages of this 
chemistry, including the deoxygenation and debenzylation following Grignard addition 
and the final aldol condensation. Due to these insurmountable issues, we moved through a 
few routes before settling instead to an iterative aldol route that would allow for rather late 
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stage incorporation of the desired olefin replacement and allow for greater flexibility in 
synthesizing additional molecules of interest. We turned to the literature to find potential 
starting materials and auxiliaries.  
As described in the introduction, Dias and coworkers published the total synthesis of 
pironetin, outlined in Scheme 3.1, which utilized three iterative aldol condensations 
through intermediate and disconnects 3.3, with Evans’ oxazolidinone auxiliaries and a 
tosylate displacement to install the unconjugated olefin, starting from 1,3-propanediol 
(3.4). 
Scheme 3.1. Retrosynthesis of Dias’s total synthesis using Evans’ oxazolidinone 
auxiliaries starting from 1,3-propane diol63 
 
We found this route to be a good starting point, however due to the inability to cleave 
the oxazolidinone directly to the corresponding aldehyde, thus adding unnecessary steps 
and chromatography, we decided to instead use Crimmins’ thiazolidinonethione 
auxiliaries.65, 96, 97 These were employed in his group’s total synthesis of pironetin, 
highlighted in the introduction and shown briefly in Scheme 3.2.66 Aldehyde 3.5 was 
prepared in eight steps from crotyl bromide and ethyl acetate. Additionally, several 
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different auxiliaries were utilized (R=benzyl, tri-methylated benzyl, isopropyl) and we 
were interested in investigating whether a single pair of non-acylated enantiomeric 
auxiliaries could efficiently yield the desired diastereomers. Most importantly, in contrast 
to the oxazolidinone auxiliaries, the thiazolidinonethiones can be cleaved directly to the 
aldehyde using DIBAL-H. Further, the un-acylated auxiliary can be recovered and reused, 
providing sustainability.  
Scheme 3.2. Crimmins’ total synthesis utilized thiazolidinonethione auxiliaries66 
 
3.2.2 Retrosynthesis and Synthesis of Auxiliaries  
Utilizing the starting material and general disconnects from Dias’ total synthesis and 
the Crimmins’ auxiliary, the retrosynthetic analysis of 4-fluorophenyldemethylpironetin 
(3.13) is outlined in Scheme 3.3. We envisioned formation of the ,-unsaturated lactone 
through a cis-selective Horner-Wadsworth Emmons reaction with aldehyde 3.6 followed 
by treatment with acid to yield 3.2. Aldehyde 3.6 can be obtained from the sequential 
Grignard addition, deoxygenation, and aldol condensation with aldehyde 3.7, which can be 
derived from iterative aldols going through aldehyde 3.8. The starting material, 1,3- 
propane diol (3.4) is readily available and the aldol condensations can easily be scaled up 
to several gram quantities. To begin our synthesis, we decided to use phenylalanine-derived 
chiral auxiliaries as one of the aldol intermediates was already published and characterized 
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Scheme 3.3. Retrosynthesis of 4-fluorophenyldemethylpironetin 
 
and we found the chemistry to be highly reproducible.98 These auxiliaries were easily 
synthesized in large quantities from D- or L-phenylalanine in three steps, Scheme 3.4.65  
Scheme 3.4. Synthesis of thiazolidinone thione chiral auxiliaries 
 
3.2.3 Synthesis of Alcohol Intermediate 3.18 
In the forward direction (Scheme 3.5), 1,3-propanediol (3.4) was treated with TBAI 
followed by benzyl bromide to yield benzyl ether 3.12. Swern oxidation of 3.12 to aldehyde 
3.13 set up for the first aldol condensation with thiazolidinonethione 3.9 via the 
uncoordinated titanium enolate to yield the Evan’s syn alcohol 3.14. Silyl protection led to 
3.15 and removal of the chiral auxiliary with DIBAL-H generated aldehyde 3.8, which was 
used for the second aldol condensation with thiazolidinonethione 3.11. Subsequent silyl 
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protection to 3.17 and removal of the auxiliary revealed aldehyde 3.7. Addition of 4-
fluorophenyl magnesium bromide yielded alcohol 3.18 as a pair of diastereomers, which 
were both carried forward.   
It was envisioned that benzylic deoxygenation and debenzylation could occur in a similar 
way as accomplished in the phenylpironetin synthesis by Dr. Huang (Scheme 3.6).99, 100 
Alcohol 3.19 was oxidized to the corresponding aldehyde and then subjected to Grignard 
addition to provide secondary alcohol 3.20, which activated with trifluoroacetic 
anhydride and deoxygenated with Pd/C and H2 under a balloon. This concurrently 
deoxygenated and debenzylated the molecule to furnish alcohol 3.21 (Dr. Huang’s 
unpublished results). 
Scheme 3.5. First half of the synthesis of 4-fluorophenyldemethylpironetin 
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3.2.4 Deoxygenation and Debenzylation Optimization 
Attempts to accomplish the same deoxygenation and debenzylation sequence with the 
4-fluorophenyldemethylpironetin derivative failed, Scheme 3.7.  Conversion of alcohol 
3.18 to trifluoroacetate 3.18a proceeded cleanly and fully. However, neither the 
deoxygenation nor the debenzylation would readily occur. Initially, we believed that the 
Pd was getting quenched due to the various reactions involving sulfur-containing 
molecules in the synthesis leading up to 3.18, however even when filtering and adding 
Scheme 3.6. Key conversion in the phenylpironetin synthesis 
 
fresh Pd (up to stoichiometric amounts) the reaction never went to completion. Altering 
the solvent resulted in partial or full TBS deprotection, increasing the pressure for short 
periods of time led to starting material and TBS deprotection.  
Scheme 3.7. Initial attempt at deoxygenation and debenzylation 
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To evaluate whether the fluorine or the route was the issue, the 
phenyldemethylpironetin intermediate was synthesized (3.23) from aldehyde intermediate 
3.7 (Scheme 3.8). A crude and small-scale conversion to the trifluoroacetate followed by 
Pd/C and H2 led to about 50% deoxygenation and debenzylation over a few hours, 
suggesting that the fluorine was inhibiting reactivity. Additionally, the 4-chlorophenyl 
precursor was synthesized, and the deoxygenation and debenzylation was sluggish and low 
yielding, further suggesting that addition of an electron withdrawing group, such as  
Scheme 3.8. Test scheme with phenyldemethylpironetin derivative 
 
fluorine, was causing the loss of reactivity. As expected, the time and temperature required 
for the Grignard additions of phenyl, 4-chlorophenyl, and 4-fluorophenyl were remarkably 
different – from 40 minutes at 0 °C to 1.5 h at 0 °C to 18 h at room temperature. Altering 
the concentration of the reaction did not affect reaction progress, changing solvents led to 
TBS deprotection, and quantitative recovery of starting material alluded that these were 
not the issues. Alternatively, insertion into the C-O bond by the palladium species might 
have been significantly hampered due to the increased bond strength. Most puzzling, 
though, is the inability to debenzylate the alcohol on the opposite end of the molecule using 
Pd/C.  
O OTBS OTBS OBn
MgBr OH OTBS OTBS OBn
OTBS OTBS OH
1) TFAA, DMAP
2) H2. Pd/C
3.7
H
3.22 75%
3.23 crude mixture
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As a workaround, the Barton McCombie deoxygenation sequence was attempted 
(Scheme 3.9). The Barton McCombie begins with conversion of the alcohol into the 
thiocarbonate, followed by radical-mediated deoxygenation. This sequence is traditionally 
used for deoxygenation of secondary alkyl hydroxyl groups with few published examples 
of benzylic alcohol deoxygenation.101-103 Activation of the benzylic alcohol was 
accomplished with 1,1’-thiocarbonyldiimidazole to give carbothioate 3.24, and heating 
with HSnBu3 and AIBN in toluene completed the deoxygenation, yielding 3.25.  
Scheme 3.9. Barton McCombie deoxygenation   
 
The next challenge was the benzyl ether deprotection. Initially, the Pd/C and H2 
hydrogenolysis was successful, however after this old bottle of Pd/C rapidly ran out and a 
new bottle was used, the chemistry no longer worked (Entry 1). Table 3.1 describes the 
optimization. As treatment with Pd/C in EtOAc was giving very low yields after long 
amounts of time at atm and high pressures, EtOH/EtOAc mixtures and straight EtOH 
(Entries 2 and 3) were used as the solvent, however this led to no improvement as the TBS 
groups started to come off. Switching to Pd(OH)2 worked decently one time on very small 
scale (Entry 4), however further attempts were unsuccessful. Throughout all of the Pd 
  
44 
usage, the solvent and starting material were stirred with activated charcoal for one hour 
and up to overnight in an attempt to remove anything which would quench the palladium. 
Additionally, the unfinished reaction was filtered to remove the Pd/C and fresh Pd/C was 
added. In addition to Pd species, in situ generated Li-naphthalide was added (Entry 5), 
however this resulted in complete recovery of starting material.104 Further, utilizing 
ammonium formate as a hydrogen transfer reagent in the presence of catalytic Pd/C (Entry 
6) was also unsuccessful.105 
Table 3.1. Optimization of benzyl ether deprotection 
 
Entry Conditions Temperature Yield Comments 
1 Pd/C in EtOAc RT 5-80% 
Inconsistent, altering 
pressure gives no 
change, takes >1 week 
to get any conversion 
2 
Pd/C in EtOAc/EtOH 
(various mixtures) 
RT 0-40% 
Inconsistent, takes >1 
week 
Increasing pressure 
removes TBS 
3 Pd/C in EtOH RT 0% TBS gone 
4 Pd(OH)2 RT 10-60% 
Inconsistent, takes > 1 
week 
5 Li-Naphthalide 0 °C to RT 0% 
Complete recovery of 
SM 
6 
Ammonium formate, 
Pd/C 
EtOAc/MeOH (1:1) 
Up to 70 °C in 
sealed 
container 
0% 
Complete recovery of 
SM 
7 
AlCl3, N,N-
dimethylaniline 
RT 85% 
Consistent, good on 
scale up 
Finally, AlCl3 and dimethylaniline were added, which was successful and reproducible 
(Entry 7). This reaction likely proceeds by initial coordination of the AlCl3 to the ether 
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oxygen followed by attack of the dimethylaniline to the benzylic carbon.106, 107 Overall, the 
deoxygenation, debenzylation, and oxidation sequence was improved from an inconsistent 
0-18% yield over several weeks, to a generally consistent 63% over several days (Scheme 
3.10).  
Scheme 3.10. Final optimization of deoxygenation and debenzylation chemistry 
 
The relative anti-configuration of alcohol 3.25 was confirmed by silyl deprotection 
(3.28) followed by conversion to acetonide 3.29, shown in Scheme 3.11. Using the 13C 
chemical shift analysis published by Rychnovsky and coworkers in 1990 and expanded 
upon by Evans and coworkers in the same year, the 13C NMR of crude 3.29 revealed the 
acetonide peaks at 25.3 and 24.0, consistent with the anti-diol. A syn-diol would show 
peaks at 19 and 30 ppm.108, 109   
Scheme 3.11. Synthesis of the ketal for confirmation of the anti-diol 
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3.2.5 Completion of the Synthesis 
The final steps of the total synthesis are shown in Scheme 3.12. Reaction of aldehyde 3.27 
with auxiliary 3.11 generated syn aldol product 3.30. generating alcohol 3.30. Subsequent 
silyl protection to 3.31 was followed by DIBAL-H cleavage to yield aldehyde 3.32, which 
underwent a Z-selective Horner-Wadsworth Emmons reaction with phosphonate 3.36 
(synthesis shown in Scheme 3.13) to generate the intermediate cis-alkene (3.33).64 
Treatment with acid allowed for global deprotection and lactone formation, generating the 
target molecule, 4-fluorophenyldemethylpironetin 3.2. The Z-selective Horner-Wadsworth 
Emmons followed by lactonization by acid treatment has been utilized in several total 
syntheses of pironetin and analogs.44, 45, 62 Thus, in 19 linear steps and 31 total steps 
including synthesis of the auxiliaries and phosphonate, the target molecule was obtained.  
Scheme 3.12. Completion of 4-fluorophenyldemethylpironetin  
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3.3 Discussion and Future Directions 
In conclusion, we synthesized 4-fluorophenyldemethylpironetin in an attempt to 
improve pironetin’s metabolic stability and maintain potency. Our synthesis represents the 
first reported total synthesis of a demethylpironetin analog, however improvement is still 
necessary. At this time, the difficulties encountered whilst removing grease from the final 
compound have proven insurmountable to obtaining finalized NMRs and biological data. 
Scheme 3.13. Preparation of phosphonate 3.36 
 
 
Further, pironetin does not ionize well by ESI, and so obtaining mass confirmation of the 
final product is delayed until APCI can be utilized on the Orbitrap, which also requires 
removal of grease. These disappointing set-backs will be overcome. We are currently 
performing an even larger scale up of the synthesis (>20 g of intermediate 3.17) and 
exploring alternative routes to avoid problematic transformations on scale, including the 
deoxygenation steps. Additionally, we are re-exploring the order in which the western and 
eastern portions of the molecule are assembled. While our initial attempts at elongating the 
eastern portion before derivatizing the western side were unsuccessful many years ago, it 
is certainly worth revisiting. 
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As the western olefin was identified as the major site of pironetin metabolism, 
phenylpironetin (3.1) was first synthesized by Dr. David Huang to investigate the utility of 
replacing the olefin. This synthesis was completed about half way through the total 
synthesis of 4-fluorophenyldemethylpironetin. While phenylpironetin (3.1) showed similar 
potency as compared to pironetin, phenylpironetin (3.1) did not show any improvements 
in metabolic stability. When phenylpironetin (3.1) was sent to Pharmaron for metabolite 
identification, 17 metabolites were identified after a 15-minute incubation period (Dr. 
Huang, unpublished results). Incorporation of the phenyl group enhanced oxidative 
metabolism around the entire molecule, especially around the lactone. Oxidation of nearly 
every carbon was observed by mass spectrometry, and many observed metabolites 
contained multiple oxidations. While it is highly unlikely that incorporation of a single 
fluorine atom will reverse and improve these results, completion of the biological and 
metabolic evaluations of 4-fluorophenyldemethylpironetin (3.2) is required and will be 
completed as material is available.  
One can envision a number of next generation small molecule analogs in which the 
phenyl has been decorated further or the terminal western methyl is replaced with a 
trifluoromethyl group. Before these molecules are synthesized, a better understanding of 
pironetin’s proclivity towards oxidative metabolism is critical. The evaluation of 4-
fluorophenyldemethylpironetin should provide highly useful information in this regard. 
Furthermore, due to the synthetic complexity and the seeming requirement for each 
stereocenter, methodology for the semisynthesis of olefin replacements should be 
investigated further. Additionally, total synthesis of the pironetin lactam, instead of the 
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lactone, would be an intriguing molecule to evaluate, and it is also feasible that replacement 
of some of the methyl pendants with trifluoromethyl would significantly alter metabolic 
stability.   
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Chapter 4: Synthesis and Evaluation of Pironetin-Folate 
Conjugates 
4.1 Introduction 
While tubulin-binding chemotherapeutics have potent anti-proliferative activity, 
treatment with these agents has undesired side effects, especially neurological and bone 
marrow toxicities.33, 34 Since pironetin forms a covalent bond with cysteine 316 of α-
tubulin, it is our hypothesis that the severe weight loss reported in the previous in vivo 
study could be caused by covalent off-target binding. Indeed, upon incubation of pironetin 
with the ethyl ester of glutathione, a 1:1 ratio of pironetin to glutathione-pironetin adduct 
was detected by LC-MS/MS, suggesting that pironetin can form covalent adducts with 
other proteins.45 In addition to conjugate addition of pironetin with Cys316, it is possible 
that epoxypironetin, the major metabolite, is a suitable electrophile for a broad scheme of 
nucleophiles found in vivo. To decrease these potential side effects and improve efficacy, 
we proposed to establish a proof-of-concept method for the targeted delivery of pironetin 
to ovarian cancer cells.  
The idea of selectively delivering a cytotoxic agent to a cancer cell using a targeting 
agent was first described in 1913 by Paul Ehrlich.110 The goal of targeted drug delivery is 
to selectively deliver a compound of interest to a specific cell to minimize unwanted effects 
on other cells. A multitude of techniques have been employed with varying success rates 
to accomplish this, including conjugation to proteins, small molecules, peptides, 
nanoparticles, liposomes, or some combination of these.  
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Antibody drug conjugates (ADCs) are a rapidly growing class of therapeutics that has 
required half a century of research to see FDA approval.111 So far, all approved ADCs are 
anticancer therapies, however clinical trials are ongoing for other indications, including 
rheumatoid arthritis  After the first approved ADC was withdrawn from the market in 2010 
due to increased toxicity over chemotherapy with the free drug alone, the next FDA 
approvals came in 2011 and 2013 for second generation ADCs brentuximab vedotin 
(Adcetris) and ado-trastuzumab emtansine (Kadcyla), respectively.112, 113 In 2017, both 
inotuzumab ozogamicin (Besponsa) and gemtuzumab ozogamicin (Mylotarg) were 
approved.114, 115 Many of these conjugates are approved for multiple cancer indications.  
There are currently more than 100 clinical trials at various stages investigating an ADC 
(accessed from clinicaltrials.gov). Many of these contain microtubule targeting agent 
warheads, some of which are too toxic to use without the targeting moiety. ADCs consist 
of a monoclonal antibody (mAb) linked to a cytotoxic agent. When the mAb recognizes a 
specific antigen, the ADC is internalized, usually through receptor-mediated endocytosis, 
and delivered to the lysosome. The ADC undergoes subsequent proteolytic degradation in 
the lysosome, releasing the cytotoxic agent. There are several generations of ADCs, and 
the evolution has addressed the understanding of topics such as the linker and its cleavage, 
off target effects, the bystander effect, warhead choice, and drug-to-antibody ratio.111  
While ADCs are the most well studied and represented of the tumor targeting agents, 
we decided to instead focus on a small molecule approach to remain within our laboratory’s 
and the ITDD’s capabilities. To address this preference, we chose folate conjugation. 
Conjugation to folic acid is an attractive approach because malignant tissues overexpress 
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the folate receptors as compared to normal tissue, particularly in ovarian, lung, breast, 
kidney, brain, and myeloid cancers.116, 117 Folate conjugated radio imaging agents have 
been shown to preferentially label solid tumors and the kidneys in patients over normal 
tissue.118 The folate-vinca alkaloid conjugate EC145/Vintafolide (4.1, Figure 4.1) 
advanced into phase III clinical trials against ovarian cancer, however the trial was halted 
 
Figure 4.1. Structure of the most advanced folate conjugate, Vintafolide, which utilizes 
desacetylvinblastine hydrazide (DAVLBH), a microtubule targeting agent too potent to use 
alone. 
in 2014 due to lack of improvement in progression-free survival.119, 120 Based on the 
evolution required, and still ongoing, for the development of successful ADCs, it is rather 
unsurprising that the first small molecule folate conjugate to enter clinical trials failed.111  
The membrane associated folate receptors (FR) are transporters used to bring folates 
and reduced folates into cells for use in one carbon metabolism for purine, pyrimidine, and 
amino acid biosynthesis. FRs exist as four isoforms (α, β, γ, and δ) and are identified by 
their varied expression patterns.121 FRα is anchored to the membrane by 
glycosylphosphatidylinositol (GPI) and is found in epithelial cells of the kidney, lung, 
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mammary ducts, and choroid plexus.122 FRβ is likewise membrane associated through GPI 
and found on activated myeloid cells, including spleen, placenta, and macrophages. 122-124 
FRγ is a soluble protein which is thought to ensure stability and bioavailability of reduced 
folates as it is nearly undetectable in normal serum and upregulated in folate deficient 
states.125 FRδ, now called Juno, is anchored to mammalian egg cells and facilitates 
fertilization by recognizing IZUMO1 on sperm and was found to not bind folic acid.126 The 
unique expression pattern of the folate receptors is enhanced in malignant states. FRα is 
dramatically overexpressed in most ovarian and uterine cancers while FRβ is 
overexpressed in most myeloid leukemias as well as macrophages associated with tumors 
and inflammatory diseases.117, 127-131 Preparation of several radiopharmaceutical folate 
conjugates has demonstrated that the biodistribution in humans is primarily at the tumor 
site and the kidney, but other normal tissues were largely untouched.132 Additionally, folate 
conjugates were found at sites of macrophage activation (inflammation in arthritis).133 
Therefore, if a molecule that does not display toxicity at the kidney is found, the conjugate 
should be safe. As such, utilizing the FR to selectively target human malignancies has been 
a burgeoning field for close to three decades.  
Folic acid (also known as folate or vitamin B9) binds to FRα, β, and γ with similar high 
affinity (Kd = 1.0, 1.0 and 0.4 nM, respectively).
125, 134 Binding triggers internalization of 
the ligand-bound receptors into the endosome, which has a unique environment. Folate 
receptor (or folate conjugate) containing endosomes are mildly acidic (pH ~ 5) and contain 
a high concentration of reducing thiols.135-137 It was soon discovered that folic acid tethered 
to a small molecule, liposomes loaded with small molecules, or proteins could get 
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internalized to the endosome.138, 139 Internalization was dependent upon free FR localized 
to the membrane, and so adding high concentrations of folic acid to the media or adding a 
phospholipase to cleave GPI, which holds the folate receptor at the membrane, resulted in 
elimination of internalization.140 Once inside the endosome, a slight drop in pH leads to 
conformational change to the receptor, releasing the ligand and detaching the folic acid 
from the conjugate. The warhead can then be separated from the rest of the molecule via 
an acid or thiol labile linker and diffuse across the endosomal membrane to exert its effect 
within the cell. Concurrently, the folate receptor makes its way back to the membrane, 
where it can again engage with folic acid or another conjugate molecule.141 This cycle is  
 
Figure 4.2. Mechanism of cellular internalization and cleavage of a folate conjugate. The 
folic acid moiety is in yellow and the small molecule warhead in blue.   
  
55 
depicted in Figure 4.2.        
Folate conjugates have evolved to consist of four parts: the targeting folate moiety 
(blue), a spacer (red), a self-immolative linker (green), and the small molecule warhead 
(black), as shown in Figure 4.3. The spacer is selected to enhance hydrophilicity, therefore 
 
Figure 4.3. General structure of a folate conjugate. In blue is the folic acid, the targeting 
moiety, red is the spacer, green is the cleavable linker, and black is the small molecule 
payload. Upon endocytosis, the self-immolative linker is cleaved, releasing the unmodified 
small molecule.  
halting passive diffusion of naturally greasy chemotherapeutics and, theoretically, ensuring 
that the conjugate will selectively enter only folate positive cells through the folate 
receptor. Peptide-, polyethyleneglycol- (PEG), or carbohydrate-based spacers, and 
combinations of these, have been successful in vitro and in vivo. The best spacer choice is 
quite warhead dependent as it affects the binding affinity of the conjugate to the folate 
receptor in addition to altering the chemical and physiochemical properties of the 
molecule.142 The spacer has also been shown to contribute to hepatic clearance and 
therefore maximum tolerated dose and safety.143  
Extensive work optimizing the linker has concluded that a self-immolative disulfide 
generally works best for high serum stability but rapid and selective cleavage in the thiol 
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rich endosome. When disulfide linkers were utilized, full cell killing was observed, but 
when acid labile linkers were used, often times it was found that the mildly acidic 
environment of the endosome was not enough to fully release small molecule or liposomal 
payloads.137  
Finally, it is of the utmost importance to select the right cytotoxic agent for conjugation. 
Due to the limited number of folate receptors on the cell surface and the recycle time 
required, there is a limit to the concentration of small molecule that will accumulate within 
a cell. Further, it’s been shown that even upon internalization, tritiated folic acid or folate 
conjugates do not always unload and are often recycled back to the surface, further limiting 
the concentration of compound to reach the cell.144 Endocyte has reported unpublished 
results in which they measured only 1-5 μM of various cytotoxic agents within cells, 
meaning that molecules must have low to sub-nanomolar potencies in order to affect 
cellular activity.142 With such a multifaceted mechanism of internalization, there are many 
processes that must be correctly balanced in order to achieve an active molecule. When 
molecules do not display the desired activity, often it is difficult to logically improve the 
outcome.145,146 
4.2 Design and Synthesis of the First Generation Pironetin-Folate 
Conjugate and a Camptothecin-Conjugate Positive Control  
Our first proof-of-concept pironetin conjugate 4.2 is based on the design of Vintafolide. 
Utilizing the spacer and a similar disulfide containing linker adapted to release the alcohol 
rather than a hydrazide, our proposed conjugate is shown in Figure 4.4. The conjugate 
contains folic acid (blue), a peptide spacer (red), a cleavable linker (green), and pironetin 
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(black). The synthesis of the peptide and activated pironetin is shown in Scheme 4.1. Folate 
peptide 4.3 was synthesized as previously reported using solid phase peptide synthesis on 
cysteine modified Wang resin at room temperature with PyBOP as the coupling reagent.147  
 
Figure 4.4. First generation pironetin conjugate 4.2 is made of folic acid (blue), a peptide 
spacer (red), the self-immolative disulfide linker (green), and pironetin (black). 
 
Scheme 4.1. Synthesis of the folate peptide and activated pironetin 
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The mixed disulfide 4.4 was synthesized by treating aldrithiol with β-mercaptoethanol.147 
Treatment of pironetin with triphosgene followed by disulfide 4.4 yielded activated 
pironetin carbonate 4.5. The pironetin conjugate (4.2) was synthesized by combining 
peptide 4.3 with activated pironetin 4.5 with a drop of base as shown in Scheme 4.2.  
 
 
Scheme 4.2. Convergent synthesis of pironetin conjugate 4.2 
 
Following synthesis of the first pironetin conjugate, we desired a positive control which 
would allow us to judge whether the cell system and assay were working. We turned to the 
literature and decided upon a camptothecin conjugate which was already published and 
utilized the same linker and spacer as our pironetin conjugate design.147 Camptothecin 
induces apoptosis by inhibiting topoisomerase 1. The synthesis of camptothecin conjugate 
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triphosgene. Upon clearing of the cloudy reaction, alcohol 4.4 was added. Following 
purification, peptide 4.3 and a drop of DIPEA were combined with activated camptothecin 
carbonate 4.6 to yield the camptothecin conjugate 4.7.  
Scheme 4.3. Synthesis of positive control camptothecin conjugate 4.7 
 
4.3 Characterization of Pironetin Release 
With the first-generation conjugate in hand, the first step was to check whether 
pironetin would in fact be released in an unmodified form when exposed to free thiol, the 
conditions found in the endosome. Based on literature precedence, we chose to incubate 
the pironetin-folate conjugate with a 10x excess of DTT and monitor by HPLC. The results 
are shown in Figure 4.5. After one hour, the peptide and conjugate were observed, and by 
eight hours, the conjugate was undetected and only peptide remained. Pironetin is only 
weakly UV active and was not observed significantly at 280 nm, so we therefore repeated 
the experiment and monitored by LC-MS to confirm unmodified pironetin release, Figure 
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the standards. Additionally, as pironetin forms a covalent adduct with cysteine of α-tubulin 
and GSH, we also incubated pironetin with DTT as a control and saw very minimal to no 
adduct formation by UV (monitored at 220, Figure 4.7).  
 
Figure 4.5. Conversion of conjugate to peptide is rapid, but pironetin is not UV active. 
 
Figure 4.6. Pironetin is released from the conjugate upon incubation with DTT as 
confirmed by LC-MS. 
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Figure 4.7. Pironetin, when treated with 10x excess DTT, forms a very minor new peak 
after an overnight incubation. 
4.4 Selection and Characterization of Cell Lines for Folate Conjugate 
Evaluation 
With the knowledge that unmodified pironetin is released from the conjugate under 
reducing conditions in vitro, the next question was whether the conjugate would be 
internalized by binding to the folate receptor, leading to endocytosis and pironetin release. 
We chose two ovarian cancer cell lines with a reported range of folate receptor expression: 
IGROV-1 with very high folate receptor expression and SK-OV-3 with low levels.148, 149 
As internalization by the folate receptor is expected to be competitively inhibited by excess 
folic acid, we adapted these cells to survive under folate-free conditions over six months. 
Normal RPMI 1640 media + 10% FBS + pen/strep contains 2.3 μM folic acid, and the 
binding affinity of FRα for folic acid is < 1 nM. After adaptation to folate free (FF) 
conditions, the media with the additives contained < 1 nM of folic acid, which is near the 
folic acid concentration in serum (0.3 nM). Additionally, it’s been reported that FRα is 
saturated at folic acid concentrations above 50 nM (under equilibrium conditions) and that 
under non-equilibrium conditions, 120 nM folic acid is enough to saturate the receptor.122, 
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150 In the next sections, cell lines which were adapted to folate free (FF) media (IGROV-1 
and SK-OV-3) will be notated as FF IGROV and FF SKOV.  
Following adaptation, we attempted to confirm the relative levels of folate receptor 
expression using Western blot and an ELISA kit from cell lysates.  Unfortunately, these 
efforts were unsuccessful. A suitable antibody for Western blotting was not identified and 
the ELISA kits were inconsistent across multiple attempts, leading to data which both 
confirmed and contradicted literature reports from the same samples. Reproducibly 
detecting FRα in cells and tissues remains a challenge in the field. While many detection 
methods have been developed, FRα is marked by a complex secondary structure and a set 
of post-translational modifications leading to a reduction in reproducibility. We thus 
carried forward with the assumption that IGROV-1 had very high levels of FR and SKOV-
3 had low levels. 
4.5 Confirmation of Camptothecin Conjugate Activity and 
Internalization 
The camptothecin conjugate (4.7) was evaluated in IGROV and SKOV cell lines which 
were adapted to FF conditions (FF IGROV and FF SKOV) utilizing the MTT assay. To 
assess FR mediated internalization, 50 μM of folic acid was added to the media. Results 
are shown in Figure 4.8. In IGROV cells, the camptothecin conjugate shows similar 
activity as compared to camptothecin, and most importantly, this activity is significantly 
decreased when 50 μM folic acid (FA) is added. To further support receptor mediated 
internalization, when the camptothecin conjugate is dosed for one hour, activity was 
partially maintained. This supports the internalization dynamics of the folate receptor. 
When IGROV and SKOV cells were treated with tritiated folic acid, rapid internalization 
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was observed followed by steady state internalization. Consistent with previous studies 
monitoring folic acid intake, the majority of the labeled folic acid remained bound to the 
receptor and was not released into the cell.144 This can be extrapolated to folate conjugates 
and is another reason that conjugates require such high potency to achieve activity. 
Nonetheless, our camptothecin conjugate maintained some activity when dosed for only 
an hour, further indicating receptor mediated internalization.  
 
Figure 4.8. Camptothecin conjugate 4.7 shows folate receptor mediated activity. FA 
competition assays were performed with 50 μM FA. 
4.6 First Generation Pironetin Conjugate Activity  
With the knowledge that our positive control was performing as expected, we began 
evaluating the first pironetin conjugate for cytotoxicity. The results are shown in Figure 
4.9. In both cell lines, the conjugate lost a significant amount of activity, but more 
concerning is that addition of 250 μM FA does not alter activity, indicating non-folate 
receptor mediated internalization.  
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Figure 4.9. Evaluation of pironetin conjugate 4.2 in FF adapted cells. FA competition 
assays were performed with 250 μM FA. 
We also showed that treatment with folic acid concurrently with pironetin did not alter 
the activity (Figure 4.10). Finally, we set up a qualitative assay looking for internalization 
and release of pironetin and the conjugate utilizing tandem mass spectrometry. Regardless 
of folate receptor mediated internalization or not, we were seeing some activity in the 
IGROV cell line upon dosing, indicating that a xenobiotic was entering the cell, and 
therefore we needed to determine that pironetin was being released and not a modified, 
inactive version of pironetin. One of our concerns upon engaging in pironetin-folate 
conjugate research was specifically putting pironetin, a Michael acceptor, into a thiol rich 
environment, like the endosome. Our group has previously reported that pironetin does 
react with glutathione, but it is reversible.45 In order to answer some of these questions, 
pironetin (1.1) and the pironetin conjugate (4.2) were dosed to cells at the high 
concentration utilized in the dose response. As a control, cells were treated with FF media  
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Figure 4.10. Confirmation that addition of 50 μM FA does not alter the activity of 
pironetin (n=1). 
containing the same concentration of DMSO. Samples were then worked up as described 
in the SI and injected onto the Orbitrap Velos using a targeted method looking specifically 
for pironetin, the folate conjugate, the folate peptide, and the pironetin mono-ethyl GSH 
adduct. The data is shown in Figure 4.11.  
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Figure 4.11. Internalization of pironetin conjugate. Pironetin is seen after treatment alone 
and after conjugate treatment. Retention times are slightly different due to solubility of the 
crude cell samples.  
As expected, when cells are treated with pironetin, pironetin is observed inside the cell. 
When the pironetin conjugate is dosed, the masses corresponding to pironetin, the 
conjugate, and the pironetin-glutathione adduct are observed. Although this was a rather 
messy assay, this tells us that the activity we see in the cell-based assays is due to pironetin 
getting released internally in an unmodified form. However, internalization is not folate 
receptor mediated, meaning further exploration was necessary.   
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4.7 Second Generation Pironetin Conjugate Synthesis and Activity  
Previous folate conjugate SAR published by the Low group and Endocyte highlighted 
the importance of the spacer unit for controlling receptor mediated endocytosis. In addition 
to improving solubility, the spacer physically separates folic acid from the  
Scheme 4.4. Synthesis of the second-generation pironetin conjugate 4.8 
 
warhead, encouraging the binding affinity of the conjugate to remain close to that of folic 
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conjugate was evaluated in the IGROV and SKOV cell lines in the presence and absence 
of excess folic acid. These results are shown in Figure 4.12. 
 
 
Figure 4.12. Evaluation of the second-generation conjugate (4.9). FA competition assays 
were performed with 250 μM FA. 
We observed similar results for conjugate 4.9 compared to the full peptide spacer 
conjugate 4.2. When dosed in the absence of folic acid, the PEG4 conjugate displayed 
similar potency as compared with pironetin in the IGROV cell line but lost about 1000x 
activity against the SKOV cell line. When 250 μM of FA was added, no change was 
observed in either cell line.  
4.8 Discussion 
As a proof of concept tumor targeting approach utilizing pironetin, we synthesized two 
folate conjugates. The folate receptor is overexpressed in most ovarian cancers and by 
targeting this, we hypothesized that the off-target effects which culminated in weight loss 
in the reported mouse in vivo study could be minimized.39 This was also the first endeavor 
to utilize a covalent modifying compound as the warhead utilizing the folate conjugate 
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approach, to our knowledge. Unfortunately, both our conjugates showed significantly 
decreased activity as compared to pironetin. Further, this activity was not diminished by 
excess folic acid, suggesting that internalization was occurring by a non-folate receptor 
mediated pathway.  
Our pironetin conjugate data is strikingly similar to that of an early folate small 
molecule conjugate. In 2001, the Low group published the synthesis and evaluation of 
several paclitaxel folate conjugates with the goal of improving solubility and PK properties. 
While the linker strategy was different and less selective for endosomal release, the results 
were the same as for the pironetin conjugates. The paclitaxel conjugate maintained most of 
the binding affinity for the folate receptor and mostly released in the endosome, but it failed 
to kill cells (or reduce tumor burden in mice) in a folate receptor specific manner. Addition 
of high concentrations of folic acid did not reduce activity, and the conjugate showed no 
preference for high FRα expressing cells over low FRα expressing cells. The authors 
concluded that the conjugate was still too hydrophobic, allowing for non-specific binding 
and non-receptor specific internalization. Simply altering the spacer would likely not 
address this issue, thus necessitating a more careful selection of small molecule warhead 
for the conjugates.151 Pironetin does display low water solubility,152 and so it possible, as 
with the paclitaxel conjugate, adding a hydrophilic spacer does not remedy this, therefore 
requiring an alternative targeting strategy.   
Other studies have also generated inactive or non-specific folate conjugates. In an SAR 
of Vintafolide’s development, it was found that while keeping the linker and spacer the 
same, changing the vinca alkaloid warhead from deacetylvinblastine hydrazide 
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(DAVLBH) to other vinca analogs, including some with increased or equivalent potency 
on their own, led to completely inactive conjugates. While the reasons behind this are still 
not understood, the authors hypothesized that the actual compound released in the 
endosome was not what they expected. Further, it is possible that once released in the 
endosome, the small molecules become trapped or altered by the slightly acidic 
environment.153 While we did see release of pironetin in the cells by LC-MS/MS, it is 
difficult to say whether pironetin was also getting modified and impossible to say (from 
this experiment) if pironetin was getting stuck in the endosome. Current efforts are focused 
on determining the relative affinity of the pironetin conjugates (4.2 and 4.9) as compared 
to folic acid utilizing a FITC-folate conjugate.  
Possible next steps include moving away from the folate conjugate to another targeted 
approach, specifically an ADC. One can envision conjugating pironetin to a mAb specific 
for the folate receptor, HER2, or Muc16, all of which are overexpressed in many ovarian 
cancers.154-157 Due to the potent cytotoxicity and the novel mechanism of action, pironetin 
remains an extremely interesting compound with unmet potential.  
 
4.9 General Summary and Future Directions 
Pironetin is the only natural product known to target α-tubulin; however, despite its 
novel mechanism of action, pironetin is still far from being a useful drug-like molecule due 
to poor pharmacokinetic properties and significant off-target effects. The work presented 
herein documented an attempt to improve the PK and drug-like utility of pironetin first by 
identifying the sites of metabolism, blocking the metabolism through total synthesis, and 
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characterizing a targeted pironetin-conjugate. This work demonstrated that pironetin is 
extremely metabolically labile and primarily metabolized to epoxypironetin. Our attempts 
to improve the metabolic stability by blocking epoxidation were ultimately unsuccessful, 
leading to extensive and increased metabolism along the rest of the molecule. Additional 
work to complete the biological and metabolic evaluation of 4-
flurophenyldemethylpironetin is ongoing, however barring exceedingly positive results, 
the total synthesis approach does not appear the most efficient or promising.  
Our second approach to improve pironetin’s utility focused on minimizing the off-
target toxicity, as pironetin is a covalent modifier and a microtubule targeting agent. Our 
proof-of-concept pironetin-folate conjugates were designed to selectively release pironetin 
inside cells which overexpress the folate receptor, however we found that the pironetin 
conjugates showed a significant decrease in cytotoxicity as compared to pironetin in the 
cell lines tested. This work showed that the activity was not diminished by excess folic 
acid, suggesting that internalization was occurring by a non-folate receptor mediated 
pathway, necessitating investigation of another targeting approach.      
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Chapter 5: Experimental Data 
5.1 General Chemistry Procedures 
All reactions were run under an inert atmosphere of N2 gas. Reaction solvents were 
anhydrous and of HPLC quality. All other reagents were purchased from Sigma or Fischer 
and used without further purification. Yields were calculated for material judged 
homogeneous by thin layer chromatography (TLC), nuclear magnetic resonance (NMR), 
and high performance liquid chromatography (HPLC) for final compounds. TLC was 
performed on 250 micron plates, eluting with the solvent indicated, visualized by a 254 nm 
UV lamp, and stained with potassium permanganate solution. Glassware for reactions was 
oven dried at 140 °C prior to use. Column flash chromatography was performed using silica 
gel, 60 Å, 230-400 mesh. NMR spectra were acquired on a 400 MHz instrument for 1H and 
a 100 MHz instrument for 13C unless otherwise noted. Chemical shifts for 1H NMR spectra 
are reported in parts per million (ppm) and referenced to the signal of residual 
nondeuterated solvent (7.26 ppm for CDCl3 and 7.16 for C6D6). Chemical shifts for 13C 
NMR are reported in parts per million (ppm) and referenced to the centerline of the 
deuterated solvent (77.2 ppm for CDCl3 and 128.1 for C6D6. High resolution mass 
spectrometry data were acquired on a Bruker BioTOF II ESI unless otherwise noted. 
Matrix assisted laser desorption/ionization (MALDI) for peptides and conjugates was 
collected on an AB-Sciex 5800 MALDI/TOF-MS using α-cyano-4-hydroxycinnamic acid 
as the matrix.  
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5.2 Chapter 2 Metabolite Identification 
5.2.1 Pironetin Extraction 
Pironetin was obtained from the fermentation broth of Streptomyces prunicolor strain PA-
48153 in a similar manner as reported in the patent by Kurokawa and coworkers following 
a 200L fermentation harvest (performed by the Biotechnology Resource Center at UMN), 
yielding 61 kg of cell paste and 129 kg of supernatant.158  
5.2.2 Synthesis of Epoxypironetin and Demethylpironetin.  
(5R,6R)-5-Ethyl-6-((2R,3S,4R,5S)-2-hydroxy-4-methoxy-3,5-dimethyl-6-(3-
methyloxiran-2-yl)hexyl)-5,6-dihydro-2H-pyran-2-one (epoxypironetin, M4).   
 
To a solution of pironetin (3.0 mg, 9.3 µmol) and NaHCO3 (0.77 mg, 9.3 µmol) at 0 °C in 
DCM (0.22 mL, 0.043 M) was added mCPBA (4.2 mg, 0.025 mmol). Upon consumption 
of pironetin (3 h), the reaction was diluted with DCM (3 mL) and then quenched with 
saturated aqueous Na2S2O3 (1 mL) and poured into aqueous NaHCO3 (1 mL, 10 wt % in 
water). The organic layer was washed with saturated aqueous NaHCO3 (3 mL), water (3 
mL), and then dried over Na2SO4, filtered, and concentrated under reduced pressure to 
yield crude powder, which was purified by flash column chromatography (SiO2) in 10% 
EtOAc in hexanes to yield epoxypironetin, M4), a pair of inseparable diastereomers, as a 
white viscous oil (2.9 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 7.00 (dd, J = 9.8, 6.0 Hz, 
1H), 6.02 (d, J = 9.8 Hz, 1H), 4.73 (dt, J = 9.4, 3.5 Hz, 1H), 4.26 – 4.13 (m, 1H), 3.48 (d, 
J = 10.4 Hz, 3H), 3.10 – 3.03 (m, 1H), 2.79 – 2.63 (m, 2H), 2.28 (dp, J = 10.2, 5.5 Hz, 1H), 
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2.07 (td, J = 11.3, 10.3, 6.8 Hz, 1H), 1.84 – 1.72 (m, 2H), 1.72 – 1.58 (m, 3H), 1.55 – 1.46 
(m, 1H), 1.41 (ddd, J = 14.2, 9.6, 5.3 Hz, 1H), 1.31 (d, J = 5.2 Hz, 3H), 1.14 – 0.92 (m, 
9H). 13C NMR (100 MHz, CDCl3) δ 164.8, 150.8, 121.0, 91.6, 90.9, 77.4, 77.9, 67.9, 67.1, 
61.9, 61.4, 58.6, 58.2, 55.6, 54.3, 39.2, 38.9, 37.1, 36.8, 36.7, 36.2, 34.8, 33.9, 21.0, 17.7, 
16.1, 15.3, 12.5, 12.2, 11.2, 11.1. HRMS calc’d for C19H32O5 (M+Na)+ 363.4498, found 
(M+Na)+ 363.2143. 1H NMR chemical shifts are consistent with reported values (13C not 
reported).58 Epoxypironetin was found to be >95% pure by HPLC analysis.  
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2,4-Dihydroxy-3,5-dimethylnon-7-en-1-yl)-5-ethyl-5,6-
dihydro-2H-pyran-2-one (demethylpironetin, M5).  
 
Demethylpironetin was prepared as previously described.58 To a solution of pironetin (11.4 
mg, 0.035 mmol) in DCM (1.8 mL, 0.02 M) at −78 °C was added a 15-crown-5 solution 
(0.3 M in DCM, 0.54 mL, 0.20 mmol) saturated with NaI. BBr3 (1 M in DCM, 105 µL, 
0.10 mmol) was then added dropwise to the reaction at −78 °C.  The reaction was warmed 
to 0 °C over 3 h and stirred at 0 °C for 3 h.  The reaction was diluted with Et2O and 
quenched with saturated aqueous NH4Cl (5 mL) and 15% sodium thiosulfate (5 mL).  The 
organic layers were separated and the combined aqueous layers was extracted with Et2O 
(4x).  The combined organic extracts were washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. The crude material was dissolved in Et2O (20 mL) 
and stirred overnight at rt with silica gel (1 g). This solution was filtered and the silica gel 
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was washed with EtOAc (5x). The organics were then washed with 15% sodium thiosulfate 
(20 mL), saturated NaHCO3 (20 mL), brine (20 mL), dried over Na2SO4, and concentrated. 
The crude oil was purified by flash chromatography with 40% EtOAc in hexanes (2x) and 
then by C18 chromatography (A: H2O with 0.1% TFA, B: AcCN, 30-70% B) to yield 
demethylpironetin (M5) (6.2 mg, 57%). 1H NMR (600 MHz, CDCl3) δ 7.02 (dd, J = 9.8, 
6.0 Hz, 1H), 6.03 (dd, J = 9.8, 0.9 Hz, 1H), 5.55 – 5.37 (m, 2H), 4.79 (ddd, J = 10.1, 3.6, 
2.7 Hz, 1H), 4.16 (dt, J = 10.8, 2.2 Hz, 1H), 3.57 (dd, J = 8.5, 3.5 Hz, 1H), 2.34 – 2.26 (m, 
1H), 2.12 – 2.06 (m, 1H), 2.02 – 1.94 (m, 1H), 1.92 – 1.86 (m, 1H), 1.83 (ddd, J = 14.2, 
10.1, 2.0 Hz, 1H), 1.77 – 1.64 (m, 6H), 1.55 – 1.47 (m, 1H), 0.98 (t, J = 7.5 Hz, 3H), 0.89 
(d, J = 6.8 Hz, 3H), 0.86 (d, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 164.9, 151.0, 
129.4, 127.2, 120.9, 77.7 (2 overlapping), 69.9, 39.8, 39.3, 37.6, 35.4, 34.8, 21.0, 18.1, 12.4 
(2 overlapping), 11.2.  HRMS calc’d for C18H30O4 (M+Na)+ 333.2042, found (M+Na)+ 
333.2035. NMR chemical shifts were consistent with reported values.58, 88 
Demethylpironetin was found to be >95% pure by HPLC analysis. 
 
5.2.3 Metabolite Identification in Human Liver Microsomes 
5.2.3.1 Microsomal Incubation 
Metabolism reactions were run in a microcentrifuge tube while shaking at 37 °C. Reaction 
solvents were of HPLC quality. Pooled human liver microsomes were purchased from 
Fisher Scientific and were of mixed gender.  
The following stock solutions were created: 
• 0.1 M Tris buffer, pH 7.4 
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• Pironetin (solubilized in DMSO and diluted with Tris buffer to 50 mM, final 
DMSO concentration <0.1%) 
• NADPH Regeneration Buffer A (20 mg/mL glucose-6-phosphate, 20 mg/mL 
NADP, 13.3 mg/mL MgCl2•6 H2O) in Tris buffer 
• NADPH Regeneration Buffer B (40 U/mL glucose-6-phosphate dehydrogenase, 5 
mM sodium citrate) in Tris buffer 
• Positive Control: verapamil (solubilized in DMSO and diluted with Tris buffer to 
10 mM, final DMSO concentration <0.1%) 
The following reactions were set up at 37 °C on a microshaker for pironetin and the 
verapamil positive control:  
Reaction 1: Microsomes (50 µL, final concentration 1 mg/mL) were added to Tris buffer 
(860 µL). NADPH regeneration buffer A (50 µL) and the NADPH regeneration buffer B 
(20 µL) were added. The reaction was allowed to incubate at 37 °C for 15 min, at which 
time the reaction was stopped with the addition of ice-cold acetonitrile (200 µL).  
Reaction 2: Microsomes (50 µL, final concentration 1 mg/mL) were added to Tris buffer 
(860 µL), and either pironetin or the verapamil stock solution (20 µL) was added. The 
reaction was allowed to incubate at 37 °C for 15 min, at which time the reaction was 
stopped with the addition of ice-cold acetonitrile (200 µL).  
Reaction 3: Microsomes (100 µL, final concentration 1 mg/mL) were added to Tris buffer 
(1.72 mL) and either pironetin or verapamil stock solution (40 µL) was added. NADPH 
regeneration buffer A (100 µL) and the NADPH regeneration buffer B (40 µL) were added. 
The reaction was allowed to incubate at 37 °C for given amounts of time (2, 4, 8, 15, 30, 
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or 60 min), at which time 250 µL was removed and quenched with ice-cold acetonitrile 
(150 µL).   
Reaction work-up: Following protein precipitation with acetonitrile, to each above 
sample was added EtOAc (800 µL) and water (100 µL). The samples were vortexed and 
then centrifuged at 14,000 rpm for 5 min. The organic layer was then transferred to a new 
vial and dried under a flow of nitrogen. Samples were then taken up in 20% acetonitrile in 
water (150 µL) and filtered prior to LC-MS/MS analysis. 
 
5.2.3.2 LC-MS/MS Method 
Prepared metabolism samples were injected onto a NanoLC-Ultra 2D HPLC system 
equipped with a 5 µL injection loop. Separation was performed on a C18 column (Synergi 
2.5 um Max-RP 100 A column, 100 x 3 mm) using a mobile phase consisting of water + 
0.1% formic acid (A) and acetonitrile + 0.1% formic acid (B) at a flow rate of 400 µL/min. 
The elution gradient conditions are as follows: column was equilibrated in 20% B prior to 
injection. Following sample injection, the gradient was increased to 62% B over 20 min, 
and then increased to 99% B over an additional min. The gradient was held at 99% B for 1 
min, after which the gradient was reduced to 50% B over an additional min. The gradient 
was then held for an additional 10 min at 50% B. The injected sample volume was 5 µL. 
Samples were analyzed by HPLC-APCI+-MS/MS atmospheric pressure chemical 
ionization (APCI) in positive mode using an LTQ Orbitrap Velos instrument. The APCI 
source was heated at 250 °C. Source voltage was 3.7 kV, sheath gas and auxiliary gas flow 
rates were 30 and 5 arbitrary units, respectively; capillary temperature was 300 °C.  
  
78 
The LTQ Orbitrap Velos was operated with two scan events. The first scan event was a 
full FTMS scan in positive mode over a mass range of 50-1000 m/z with a resolving power 
of 15000. The second scan event was HCD MS2 fragmentation of the top five ions selected 
from the first scan event with an isolation width of 2.0 m/z. Normalized collision energy 
was set to 50% with an activation time of 0.1 ms.  
The data were processed using the XCaliber software. The masses for pironetin and its 
metabolites were extracted from the full scan data to identify peak retention times and then 
evaluated for structure using MS fragmentation patterns. Epoxypironetin was >95% pure 
for this analysis and demethylpironetin was found to be 86% pure for this experiment 
(demethylpironetin was later resynthesized and found to be >95% pure for the cell 
cytotoxicity studies).  
 
5.2.4 Cell Viability Assay 
Cell lines (A2780 and A2780CP) were a generous gift from the Skubitz lab at the 
University of Minnesota. Cells were grown in a 5% CO2 atmosphere at 37 °C in tissue 
culture dishes. A2780 and A2780CP cells were grown in RPMI 1640 media supplemented 
with 10% fetal bovine serum (FBS) and 50 U/mL penicillin/streptomycin.  
Upon ~70% growth confluence, cells were harvested by trypsin and the pellet was washed 
with media and spun down twice before plating 50 μL of 5x104 cells/mL in each required 
well of a 96-well plate. Cells were allowed to grow for 24 h, after which cells were treated 
with 11 concentrations of pironetin, demethylpironetin, epoxypironetin, and paclitaxel as 
a control. Cells were then incubated for 48 h. 
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Cell proliferation was analyzed following published protocol for the Non-Radioactive Cell 
Proliferation Assay (MTT). Following individual treatment with compounds, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 15 μL of 12 mM stock) was added 
to the culture medium and allowed to incubate for 4 h at 37 °C. After this time, solubilizing 
solution/stop mix (150 μL, Promega) was added and the plates were set to incubate 
overnight at 37 °C, after which the absorbance was measured at 570 nm on a microplate 
reader. Each measurement was done in triplicate during each experiment on a minimum of 
two separate experiments.  
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5.3 Chapter 3 Total Synthesis of 4-Fluorophenyldemethylpironetin 
All auxiliaries and their intermediates were prepared as previously described and matched 
the literature NMR and OR values.159, 160 
 
3-(Benzyloxy)propan-1-ol (3.12).  
 
To NaH (0.557 g, 23.2 mmol) dissolved in THF (28 mL, 0.5 M)) was added 1,3-propane 
diol (1 mL, 10 mmol) dropwise. The reaction was stirred for 45 min. At this time, TBAI 
(2.57 g, 7.0 mmol) was added, followed by BnBr (1.657 mL, 14.0 mmol) dropwise. The 
reaction as allowed to stir overnight, at which time the reaction as quenched with water 
and extracted with DCM (3x). The organic layers were combined and washed with sodium 
thiosulfate followed by brine, dried over MgSO4, dried, filtered, and concentrated to yield 
the crude oil. The oil was purified by flash chromatography (0-30% EtOAc in hexanes) to 
give 3.12 as a clear oil (1.32 g, 60%). The spectral data is consistent with reported values.98 
1H NMR (400 MHz; CDCl3) δ 7.38 – 7.27 (m, 5H), 4.53 (s, 2H), 3.85 – 3.73 (t, J = 5.6 Hz, 
2H), 3.72 – 3.60 (t, J = 5.8 Hz, 2H), 1.93 (br s, 1H), 1.88 (p, J = 5.7 Hz, 2H). 
 
3-(Benzyloxy)propanal (3.13).  
 
To a solution of DMSO in DCM at −78 °C was added a solution of oxalyl chloride. The 
reaction mixture was stirred at −78 °C for 10 min, at which time 3-(benzyloxy)propan-1-
ol (3.12) was added dropwise in DCM. After 15 min, TEA was added and the solution was 
OBnO
H
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allowed to stir for 5 min before warming to room temperature. After complete consumption 
of the alcohol (1 h), the reaction was quenched with saturated ammonium chloride and the 
aqueous phase was washed with DCM (3x). The organic phase was washed with saturated 
sodium bicarbonate, brine, dried (Na2SO4), and concentrated in vacuo. The crude reaction 
mixture was purified (CombiFlash, 0-40% EtOAc in hexanes) to yield aldehyde (3.13) as 
a clear oil (0.854 g, 86%). The spectral data is consistent with reported values.98 1H NMR 
(400 MHz, CDCl3) δ 9.81 (s, 1H), 7.39 – 7.28 (m, 5H), 4.55 (s, 2H), 3.83 (t, J = 6.1 Hz, 
2H), 2.71 (td, J = 6.1, 1.9 Hz, 2H).  
 
(2S,3R)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-(benzyloxy)-3-hydroxy-2-
methylpentan-1-one (3.14). 
 
To a stirred solution of thiazolidinone thione (3.9, 1.95 g, 7.36 mmol) and dry DCM (5.0 
mL, 1M) at 0 °C was added TiCl4 (0.855 mL, 7.76 mmol) dropwise, upon which the 
mixture turned orange. If necessary, additional DCM (< 1 mL) was added to keep the 
reaction solvated. After stirring for 5 min, DIPEA (1.42 mL, 8.1 mmol) was added 
dropwise. The dark purple reaction mixture was allowed to stir for an additional 40 min at 
0 °C, at which time NMP (N-methyl-2-pyrrolidone, 1.42 mL, 14.73 mmol) was added 
dropwise, and the reaction was let to stir for 15 min. At this time, the mixture was cooled 
to −78 °C and aldehyde (3.13, 0.81 g, 4.91 mmol) in 0.5 mL DCM was added dropwise. 
The reaction was stirred at −78 °C for 2 h, and then warmed to 0 °C and let to stir for 1 h. 
After complete consumption of the aldehyde, the reaction mixture was quenched with 
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saturated ammonium chloride. The aqueous layer was extracted with DCM (3x), and the 
combined organic layers were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude product mixture was purified by silica-gel 
chromatography (CombiFlash, 0-20% EtOAc in hexanes) to give the syn aldol product 3.14 
as a yellow oil (1.5 g, 71%). The spectral data is consistent with reported values.98  
[𝛼]𝐷
26 +134.5 (c=1, CHCl3) 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.11 (m, 10H), 5.24 (m, 
1H), 4.49 (tt, J = 6.9, 3.4 Hz, 1H), 4.45 (s, 2H), 4.10 (dp, J = 10.2, 4.1, 3.5 Hz, 1H), 3.71 
– 3.48 (m, 2H), 3.32 (dd, J = 11.6, 7.1 Hz, 1H), 3.23 (s, J = 2.3 Hz, 1H), 3.18 (dd, J = 13.2, 
3.8 Hz, 1H), 2.98 (dd, J = 13.2, 10.6 Hz, 1H), 2.82 (d, J = 11.5 Hz, 1H), 1.87 – 1.58 (m, 
2H), 1.21 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 201.5, 177.8, 138.0, 136.6, 
129.6 (2C), 129.0 (2C), 128.6 (2C), 127.9 (2C), 127.4 (2C), 73.5, 71.8, 69.2, 68.8, 43.9, 
36.8, 34.0, 32.3, 11.1. HRMS calc’d for C23H27NO3S2 (M+Na)+ 452.5822, found (M+Na)+ 
452.1318. 
 
(2S,3R)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-(benzyloxy)-3-((tert-
butyldimethylsilyl)oxy)-2-methylpentan-1-one (3.15).  
 
To a solution of alcohol (3.14, 0.99 g, 2.305 mmol) in DCM (19.70 mL, 0.117 M) at 0 °C 
was added 2,6-lutidine (0.537 mL, 4.61 mmol) and then TBSOTf (0.794 mL, 3.46 mmol) 
dropwise. The reaction was warmed to rt and upon consumption of the starting material, 
the mixture was quenched with sodium bicarbonate. The aqueous layer was extracted with 
DCM (3x), the combined organic layers were washed with brine, and then dried (Na2SO4), 
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filtered, and concentrated under reduced pressure. The crude oil was purified by column 
choromatography (CombiFlash, 0-20% EtOAc in hexanes) to yield 3.15 as a yellow oil 
(0.985 g, 79%). [𝛼]𝐷
26 +131.2 (c 1, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.19 (m, 
10H), 5.12 (ddd, J = 10.6, 7.1, 3.9 Hz, 1H), 4.54 – 4.35 (m, 3H), 4.06 (q, J = 5.5 Hz, 1H), 
3.54 – 3.38 (m, 2H), 3.24 – 3.15 (m, 2H), 2.98 (dd, J = 13.2, 10.6 Hz, 1H), 2.78 (d, J = 
11.4 Hz, 1H), 1.95 – 1.68 (m, 2H), 1.20 (d, J = 6.7 Hz, 3H), 0.81 (s, 9H), -0.05 (s, 6H). 13C 
NMR (100 MHz, CDCl3) δ 201.1, 177.0, 138.6, 136.8, 129.6 (2C), 129.0 (2C), 128.5 (2C), 
127.8 (2C), 127.6, 127.3, 73.2, 72.2, 69.5, 66.4, 44.7, 36.7, 35.0, 32.2, 25.9 (3C, TBS), 
18.2, 13.8, -4.3, -4.5.HRMS calc’d for C29H41NO3S2Si (M+Na)+ 566.8452, found (M+Na)+ 
566.2205. 
 
(2S,3R)-5-(Benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentanal (3.8). 
 
To a solution of 3.15 (129 mg, 0.237 mmol) in DCM (2.64 mL, 0.09 M) at −78 °C was 
added DIBAL-H (0.474 mL, 1 M in DCM) dropwise. The reaction went clear almost 
immediately upon addition of DIBAL-H. When clear, saturated Rochelle’s Salt was added 
and the reaction was allowed to stir at rt for 1 hour. At this time, the aqueous layer was 
extracted with DCM (3x), and the combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated under reduced pressure. The crude reaction mixture was 
purified by chromatography (30% EtOAc in hexanes) to yield aldehyde 3.8 as a clear oil 
(62 mg, 78%), which was used immediately in the next reaction. 1H NMR (400 MHz, 
CDCl3) δ 9.71 (s, 1H), 7.27 – 7.18 (m, 5H), 4.41 (q, J = 11.9 Hz, 2H), 4.25 (ddd, J = 7.3, 
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5.6, 3.6 Hz, 1H), 3.45 (tq, J = 6.9, 3.9, 3.5 Hz, 2H), 2.44 – 2.38 (m, 1H), 1.83 – 1.65 (m, 
2H), 0.99 (d, J = 7.0 Hz, 3H), 0.79 (s, 9H), -0.01 (d, J = 9.1 Hz, 6H). 
 
 
 
 
(2R,3S,4R,5R)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-7-(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-2,4-dimethylheptan-1-one (3.16).  
 
To a stirred solution of thiazolidinone thione (3.11, 0.443 g, 1.67 mmol) and dry DCM 
(1.12 mL, 1M) at 0 °C was added TiCl4 (0.194 mL, 1.76 mmol) dropwise, upon which the 
mixture turned orange. If necessary, additional DCM (~ 0.2 mL) was added to keep the 
reaction solvated. After stirring for 5 min, DIPEA (0.320 mL, 1.83 mmol) was added 
dropwise. The dark purple reaction mixture was allowed to stir for an additional 40 min at 
0 °C, at which time NMP (0.321 mL, 3.33 mmol) was added dropwise, and the reaction 
was let to stir for 15 min. At this time, the mixture was cooled to −78 °C and aldehyde (3.8, 
0.374 g, 1.112 mmol) in 0.5 mL DCM was added dropwise. The reaction was stirred at 
−78 °C for 2 h, and then warmed to 0 °C and let to stir for 1 h. After complete consumption 
of the aldehyde, the reaction mixture was quenched with saturated ammonium chloride. 
The aqueous layer was extracted with DCM (3x), and the combined organic layers were 
washed with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
crude product mixture was purified by silica-gel chromatography (CombiFlash, 0-20% 
EtOAc in hexanes) to give the syn aldol product 3.16 as a yellow oil (0.539 g, 81%). 1H 
NMR (400 MHz, CDCl3) δ 7.33 – 7.26 (m, 10H), 5.34 (td, J = 7.0, 3.5 Hz, 1H), 5.03 – 4.93 
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(m, 1H), 4.49 – 4.43 (m, 2H), 4.14 – 4.06 (m, 1H), 3.99 (td, J = 6.8, 2.4 Hz, 1H), 3.46 (td, 
J = 6.8, 3.1 Hz, 2H), 3.33 (dd, J = 11.5, 7.3 Hz, 1H), 3.14 (dd, J = 13.2, 3.6 Hz, 1H), 3.10 
(d, J = 2.3 Hz, 1H), 2.99 (ddd, J = 13.3, 10.5, 3.2 Hz, 1H), 2.85 (dd, J = 11.6, 2.9 Hz, 1H), 
1.86 (q, J = 6.6 Hz, 2H), 1.71 (td, J = 6.5, 2.4 Hz, 1H), 1.26 – 1.20 (m, 3H), 1.01 (d, J = 
6.8 Hz, 3H), 0.88 (d, J = 8.0 Hz, 9H), 0.08 (s, 6H). 13C NMR (100z MHz, CDCl3) δ 201.1, 
178.5, 138.5, 136.6, 129.5 (2C), 129.1 (2C), 129.0, 128.5 (2C), 127.6 (2C), 127.4, 73.5, 
73.2, 72.3, 69.2, 67.4, 41.7, 39.0, 37.0, 34.9, 31.4, 26.0 (3C), 18.2, 12.5, 8.6, -3.8, -4.2. 
HRMS calc’d for C32H47NO4S2Si (M+Na)+ 624.2608, found (M+Na)+ 624.2609. 
 
(2R,3S,4S,5R)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-7-(benzyloxy)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2,4-dimethylheptan-1-one (3.17). 
 
To a solution of alcohol (3.16, 1.3 g, 2.2 mmol) in DCM (19 mL, 0.12 M) at 0 °C was 
added 2,6-lutidine (0.50 mL, 3.2 mmol) and then TBSOTf (0.74 mL, 3.2 mmol) dropwise. 
The reaction was warmed to rt and upon consumption of the starting material, the mixture 
was quenched with sodium bicarbonate. The aqueous layer was extracted with DCM (3x), 
the combined organic layers were washed with brine, and then dried (Na2SO4), filtered, 
and concentrated under reduced pressure. The crude oil was purified by chromatography 
(CombiFlash, 0->10% EtOAc in hexanes) to yield 3.17 as a yellow oil (0.97 g, 63%). [𝛼]𝐷
26 
-67.3 (c 1, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (m, 10H), 5.27 (ddd, J = 
10.6, 6.8, 3.9 Hz, 1H), 4.77 – 4.64 (m, 1H), 4.46 (s, 2H), 4.17 (t, J = 5.0 Hz, 1H), 3.69 (q, 
J = 5.7 Hz, 1H), 3.49 (td, J = 6.8, 6.1, 1.9 Hz, 2H), 3.28 – 3.13 (m, 2H), 3.00 (dd, J = 13.1, 
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10.5 Hz, 1H), 2.76 (d, J = 11.5 Hz, 1H), 1.94 – 1.72 (m, 2H), 1.67 (h, J = 6.8 Hz, 1H), 1.20 
(d, J = 6.7 Hz, 3H), 0.90 (m, 21H), 0.09 – 0.03 (m, 12H). 13C NMR (100 MHz, CDCl3) δ 
200.7, 177.2, 138.6, 136.7, 129.6 (2C), 129.0 (2C), 128.5 (2C), 127.9 (2C), 127.7, 127.3, 
73.8, 73.2, 70.5, 69.3, 66.8, 45.5, 41.6, 36.7, 35.7, 31.6, 26.2 (3C), 26.2 (3C), 18.5, 18.4, 
13.3, 11.5, -3.5, -3.6, -3.7, -4.1. HRMS calc’d for C38H61NO4S2Si2 (M+Na)+ 738.3473, 
found (M+Na)+ 738.3488. 
(2R,3S,4S,5R)-7-(Benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)-2,4-
dimethylheptanal (3.7). 
 
To a solution of 3.17 (585 mg, 0.817 mmol) in DCM (9.1 mL, 0.1 M) at −78 °C was added 
DIBAL-H (1.63 mL, 1 M in DCM) dropwise. The reaction went clear almost immediately 
upon addition of DIBAL-H. When clear, saturated Rochelle’s Salt was added and the 
reaction was allowed to stir at rt for 1 hour. At this time, the aqueous layer was extracted 
with DCM (3x), and the combined organic layers were washed with brine, dried (Na2SO4), 
and concentrated under reduced pressure. The crude reaction mixture was purified by 
chromatography (0->20% EtOAc in hexanes) to yield aldehyde 3.7 as a clear oil (366 mg, 
88%), which was used immediately in the next reaction. 1H NMR (400 MHz, CDCl3) δ 
9.68 (s, 1H), 7.35 – 7.26 (m, 5H), 4.48 (s, 2H), 4.32 (dd, J = 6.9, 1.9 Hz, 1H), 3.99 (td, J = 
6.2, 3.2 Hz, 1H), 3.47 (t, J = 6.8 Hz, 2H), 2.47 (qd, J = 6.8, 1.7 Hz, 1H), 1.86 (q, J = 6.6 
Hz, 2H), 1.74 (tt, J = 7.4, 3.8 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H), 0.89 – 0.83 (m, 21H), 0.09 
– 0.03 (m, 12H). 
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(2S,3R,4S,5R)-7-(Benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)-1-(4-fluorophenyl)-
2,4-dimethylheptan-1-ol (3.18). 
 
(4-Fluorophenyl)magnesium bromide (1.10 mL, 1.10 mmol, 1 M in THF) was added 
dropwise to a solution of aldehyde 3.7 (374 mg, 0.735 mmol) in THF (6.23 mL, 0.12 M) 
at 0 °C. The reaction was warmed to rt and stirred overnight, at which time saturated NH4Cl 
was added and the aqueous layer was extracted with EtOAc (4x). The combined organic 
layers were washed with brine, dried over sodium sulfate, and concentrated under reduced 
pressure. The crude reaction mixture was purified by chromatography (0->10% EtOAc in 
hexanes) to yield 3.18 as a clear oil (403 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 7.35 – 
7.26 (m, 5H), 7.25 – 7.16 (m, 2H), 7.04 – 6.94 (m, 2H), 4.51 – 4.43 (m, 3H), 4.27 (d, J = 
6.8 Hz, 1H), 3.91 (q, J = 5.5 Hz, 1H), 3.51 (t, J = 6.9 Hz, 2H), 2.52 (br s, 1H), 1.92 – 1.80 
(m, 4H), 0.94 – 0.88 (m, 21H), 0.61 (d, J = 6.9 Hz, 3H), 0.16 – 0.07 (m, 12H). 13C NMR 
(100 MHz, CDCl3) δ 179.2, 140.2 (d, 4JCF = 3.1 Hz), 138.6, 128.6 (d, 3JCF = 5.2 Hz, 2C), 
128.5 (2C), 127.8, 127.7 (2C), 115.2 (d, 2JCF = 21.3 Hz, 2C), 76.4, 73.2, 71.2, 67.1, 44.0, 
35.6, 35.4, 26.3 (3C), 26.2 (3C), 18.6, 18.5, 11.3, 8.2, -3.3, -3.5, -3.6, -4.0. HRMS calc’d 
for C34H57FO4Si2 (M+Na)
+ 627.9836, found (M+Na)+ 627.3664. 
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(2S,3R,4S,5R)-7-(Benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)-1-(4-
fluorophenyl)-2,4-dimethylheptyl 2,2,2-trifluoroacetate (3.18a).  
 
To a solution of alcohol 3.18 (138 mg, 0.228 mmol) in DCM (4.6 mL, 50 mM) was added 
DMAP (5.6 mg, 0.046 mmol). The reaction was cooled to 0 °C, TFAA (84 µL, 0.593 
mmol) was added dropwise, and the reaction stirred until the starting material was 
consumed by TLC. At this time, saturated NaHCO3 was added and the reaction warmed to 
RT and stirred for 15 min. The reaction was then extracted 3x DCM, the organic layers 
were combined and washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. The crude oil was then passed through a plug of silica with 30% EtOAc/hexanes 
to yield 3.18a as an oil (160 mg, 99%). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.34 (m, 5H), 
7.31 –  7.27 (m, 2H), 7.09 – 7.02 (m, 2H), 5.81 (d, J = 10.7 Hz, 1H), 4.47 –  4.38 (m, 2H), 
3.76 (q, J = 5.4 Hz, 1H), 3.46 (d, J = 6.7 Hz, 1H), 3.37 (t, J = 6.8 Hz, 2H), 1.71 – 1.50 (m, 
4H), 1.09 (d, J = 6.5 Hz, 3H), 0.98 – 0.89 (m, 18H), 0.83 (d, J = 7.0 Hz, 3H), 0.12 – 0.03 
(m, 12H).  13C NMR (100 MHz, CDCl3) δ 194.1, 164.4, 141.0, 138.5, 133.2 (2C), 130.3 
(d, 3JCF = 7.7 Hz, 2C), 128.5 (2C), 127.8, 127.7, 116.0 (d, 
2JCF = 21.8 Hz, 2C), 83.0, 73.2, 
72.2, 70.2, 66.8, 43.8, 40.5, 35.6, 26.3 (3C), 25.9 (3C), 18.8, 18.3, 10.8, 10.5, -2.8, -3.4, -
3.4, -4.1. 
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O-((2S,3R,4S,5R)-7-(Benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)-1-(4-
fluorophenyl)-2,4-dimethylheptyl) 1H-imidazole-1-carbothioate (3.24). 
 
To a solution of alcohol 3.18 (403 mg, 0.666 mmol) in DCM (16.65 mL, 0.04 M) was 
added DMAP (8.14 mg, 0.067 mmol) and 1,1’-diimidazolethione (594 mg, 3.33 mmol). 
The reaction was allowed to stir at reflux until consumption of starting material (~48 h), at 
which time the reaction was cooled and washed with water and brine. The organic layers 
were dried over Na2SO4, filtered, concentrated, and purified by chromatography (0-100% 
EtOAc in hexanes) to yield 3.24 as a light-yellow oil (307 mg, 65%). 1H NMR (400 MHz, 
CDCl3) δ 8.35 (s, 1H), 7.62 (s, 1H), 7.32 – 7.17 (m, 8H), 7.00 (ddt, J = 8.7, 4.4, 2.9 Hz, 
2H), 6.11 (d, J = 10.4 Hz, 1H), 4.49 (s, 2H), 4.16 – 4.09 (m, 1H), 3.96 (q, J = 5.5 Hz, 1H), 
3.53 (t, J = 6.5 Hz, 2H), 2.03 – 1.71 (m, 4H), 0.98 – 0.81 (m, 21H), 0.64 (d, J = 6.8 Hz, 
3H), 0.12 – -0.01 (m, 12H). 
 
(5R,6S,7R)-5-(2-(Benzyloxy)ethyl)-7-((S)-1-(4-fluorophenyl)propan-2-yl)-
2,2,3,3,6,9,9,10,10-nonamethyl-4,8-dioxa-3,9-disilaundecane (3.25).  
 
To a solution of imidazolide 3.24 (307 mg, 0.430 mmol) in toluene (24 mL, 0.018 M) was 
added HSnBu3 (1.29 mL, 1.29 mmol, 1 M in cyclohexane) and AIBN (21 mg, 0.130 mmol). 
The reaction was refluxed until the starting material was consumed (24-48 h), at which 
time the reaction was cooled and concentrated. The crude oil was purified by 
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chromatography (0-20% EtOAc in hexanes) to yield 3.25 as a clear oil (160 mg, 64%). 
[𝛼]𝐷
26 -74.5 (c 0.73, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.23 (m, 5H), 7.13 (dd, 
J = 8.3, 5.4 Hz, 2H), 6.98 (t, J = 8.5 Hz, 2H), 4.60 – 4.45 (m, 2H), 3.92 (q, J = 5.4 Hz, 1H), 
3.76 (d, J = 6.6 Hz, 1H), 3.52 (t, J = 6.9 Hz, 2H), 2.68 (dd, J = 13.5, 5.4 Hz, 1H), 2.51 (dd, 
J = 13.5, 9.5 Hz, 1H), 1.92 (dt, J = 14.0, 6.6 Hz, 1H), 1.87 – 1.74 (m, 2H), 1.73 – 1.64 (m, 
1H), 1.00 – 0.85 (m, 24H), 0.18 – 0.05 (m, 12H). 13C NMR (100z MHz, CDCl3) δ 161.4 
(1JCF = 243.4 Hz), 138.6, 137.2 (
4JCF = 3.2 Hz), 130.5 (
3JCF = 7.7 Hz, 2C), 128.4 (2C), 
127.7 (2C), 127.6, 115.0 (2JCF = 21.0 Hz, 2C), 76.4, 73.2, 71.1, 67.0, 44.0, 41.4, 38.1, 35.7, 
26.1 (3C), 26.3 (3C), 18.7, 18.4, 13.4, 11.3, -3.2, -3.4, -3.7, -3.7. HRMS calc’d for 
C34H57FO3Si2 (M+Na)
+ 611.3722, found (M+Na)+ 611.3742. 
 
(2S,3R,4S,5R)-7-(Benzyloxy)-1-(4-fluorophenyl)-2,4-dimethylheptane-3,5-diol (3.28). 
 
Silane 3.25 (15 mg, 0.025 mmol) was taken up in 1% HCl in EtOH (0.5 mL) and allowed 
to stir overnight. Upon completion, reaction was diluted with EtOAc and saturated 
NaHCO3. The aqueous layer was washed 3x EtOAc, the organic layers combine and 
washed with brine, dried over Na2SO4, filtered, and concentrated. The crude oil was 
purified by chromatography (0-100% EtOAc in hexanes) to yield 3.28 as a clear oil (7.4 
mg, 81%). 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.18 (m, 5H), 7.08 (dd, J = 8.3, 5.6 Hz, 
2H), 6.89 (t, J = 8.5 Hz, 2H), 4.48 (s, 2H), 4.08 – 3.94 (m, 1H), 3.72 (dt, J = 9.2, 4.5 Hz, 
1H), 3.60 (td, J = 9.6, 3.1 Hz, 1H), 3.45 (dd, J = 9.1, 2.7 Hz, 1H), 2.72 – 2.40 (m, 2H), 1.96 
– 1.70 (m, 3H), 1.51 (d, J = 14.5 Hz, 1H), 0.81 (d, J = 6.7 Hz, 3H), 0.70 (d, J = 7.1 Hz, 
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3H). 13C NMR (100 MHz, CDCl3) δ 161.4 (1JCF = 243.1 Hz), 137.7, 137.1 (4JCF = 3.2 Hz), 
130.6 (3JCF = 7.7 Hz, 2C), 128.7 (2C), 128.0 (2C), 127.9, 115.0 (
2JCF = 21.0 Hz, 2C), 76.2, 
75.4, 73.7, 70.6, 39.8, 39.5, 37.8, 31.5, 12.6, 12.2. 
 
(4R,5S,6R)-4-(2-(Benzyloxy)ethyl)-6-((S)-1-(4-fluorophenyl)propan-2-yl)-2,2,5-
trimethyl-1,3-dioxane (3.29). 
 
To solution of dimethoxypropane (7.55 µL, 62 µmol) and PTSA (0.2 mg, 1 µmol) in DCM 
(0.05 mL) was added diol 3.28 (7.4 mg, 21 µmol) in DCM (0.05 mL). The reaction mixture 
was stirred at rt until starting material was consumed. The reaction mixture was then poured 
into saturated aqueous NaHCO3, and the mixture was then extracted with EtOAc.  The 
EtOAc extract layers were washed with brine, dried over MgSO4, and concentrated. NMR 
analysis was carried out on the crude product (3.29) to confirm the anti 1,3-diol. 1H NMR 
(400 MHz, CDCl3) δ 7.38 – 7.27 (m, 5H), 7.10 (dd, J = 8.2, 5.5 Hz, 2H), 6.95 (t, J = 8.5 
Hz, 2H), 4.50 (s, 2H), 3.97 (dt, J = 9.2, 4.7 Hz, 1H), 3.54 (t, J = 6.5 Hz, 2H), 3.11 (dd, J = 
7.9, 2.5 Hz, 1H), 2.69 (dd, J = 13.6, 7.1 Hz, 1H), 2.49 (dd, J = 13.6, 8.0 Hz, 1H), 1.84 – 
1.73 (m, 2H), 1.66 (dq, J = 8.9, 4.7, 4.2 Hz, 2H), 1.27 (s, 6H), 0.90 (d, J = 6.7 Hz, 3H), 
0.73 (d, J = 6.7 Hz, 3H). 13C NMR (100z MHz, CDCl3) δ 161.4, 138.62, 137.1 (4JCF = 3.1 
Hz), 130.5 (3JCF = 7.7 Hz, 2C), 128.5 (2C), 128.0 (2C), 127.7, 115.0 (
2JCF = 21.1 Hz, 2C), 
100.5, 76.3, 73.4, 67.4, 66.2, 39.5, 38.3, 36.8, 31.3, 25.3, 24.0, 13.9, 12.4. 
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(3R,4S,5R,6S)-3,5-bis((tert-Butyldimethylsilyl)oxy)-7-(4-fluorophenyl)-4,6-
dimethylheptan-1-ol (3.26).  
 
Benzyl ether 3.25 (20.0 mg, 34 μmol) was taken up in DCM (0.290 mL, 0.118 M) and 
dimethylaniline (84 μL, 0.68 mmol) was added dropwise. AlCl3 (72 mg, 0.54 mmol) was 
then added in one portion and the reaction was allowed to stir until starting material was 
consumed (~1 h), at which time the reaction was cooled to 0 °C and slowly quenched with 
1 M NaHSO4 (1 mL). The mixture was warmed to rt and partitioned between EtOAc and 
saturated aqueous NaHCO3 (10 mL each). The organic layer was washed with brine, dried 
over MgSO4, filtered, and concentrated under vacuum. The crude oil was purified by flash 
chromatography (0-10% EtOAc in hexanes) to give alcohol 3.26 as a pale-yellow oil (9.4 
mg, 56%). 1H NMR (400 MHz, CDCl3) δ 7.14 – 7.03 (m, 2H), 6.96 (t, J = 8.7 Hz, 2H), 
3.88 – 3.70 (m, 2H), 3.69 – 3.57 (m, 2H), 2.60 (dd, J = 13.4, 6.0 Hz, 1H), 2.45 (ddd, J = 
15.2, 10.3, 5.5 Hz, 1H), 1.78 (ddt, J = 22.1, 14.1, 6.3 Hz, 3H), 1.49 (dq, J = 14.6, 5.0 Hz, 
1H), 0.97 – 0.83 (m, 24H), 0.13 – 0.04 (m, 12H). 13C NMR (100z MHz, CDCl3) δ 161.4 
(d, 1JCF = 243.6 Hz), 137.5 (d, 
4JCF = 3.1 Hz), 130.6 (d, 
3JCF = 7.7 Hz, 2C), 115.2 (d, 
2JCF 
= 21.1 Hz, 2C), 75.6, 72.6, 60.0, 43.6, 41.5, 38.2, 37.0, 26.3 (3C), 26.1 (3C), 18.7, 18.3, 
14.1, 12.1, -3.2, -3.6, -3.8, -4.0. HRMS calc’d for C27H51FO3Si2 (M+Na)+ 521.3253, found 
(M+Na)+ 521.3243. 
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(3R,4S,5R,6S)-3,5-bis((tert-Butyldimethylsilyl)oxy)-7-(4-fluorophenyl)-4,6-
dimethylheptanal (3.27). 
 
To a solution of alcohol 3.26 (28 mg, 0.056 mmol) in DCM (0.45 ml, 0.125 M) was added 
4 Å molecular sieves (28 mg) and NMO (7.8 mg, 0.066 mmol). The mixture was cooled to 
0 °C and allowed to stir for 15 min, after which a solution of TPAP (2 mg, 0.0056 mmol) 
in DCM (0.1 mL) was added and allowed to stir at 0 °C. After the starting material was 
consumed, the reaction was diluted with 20% EtOAc in hexanes (2 mL) and filtered 
through silica. Aldehyde 3.27 was used without further purification in the next reaction. 1H 
NMR (400 MHz, CDCl3) δ 9.74 – 9.53 (s, 1H), 6.98 – 6.94 (m, 2H), 6.84 – 6.79 (m, 2H), 
4.01 (q, J = 5.5 Hz, 1H), 3.53 (td, J = 7.3, 6.6, 3.0 Hz, 1H), 2.52 – 2.45 (m, 1H), 2.37 – 
2.25 (m, 3H), 1.70 – 1.60 (m, 2H), 0.82 – 0.73 (m, 24H), -0.01 –  -0.08 (m, 12H). 
 
(2S,3R,5R,6S,7R,8S)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5,7-bis((tert-
butyldimethylsilyl)oxy)-2-ethyl-9-(4-fluorophenyl)-3-hydroxy-6,8-dimethylnonan-1-
one (3.30).  
 
To a stirred solution of thiazolidinone thione (3.10, 52.7 mg, 0.188 mmol) and dry DCM 
(1 mL) at 0 °C was added TiCl4 (20.6 µL, 0.188 mmol) dropwise, upon which the mixture 
turned orange. If necessary, additional DCM (~ 0.1 mL) was added to keep the reaction 
solvated. After stirring for 20 min, DIPEA (32.7 µL, 0.188 mmol) was added dropwise. 
The dark purple reaction mixture was allowed to stir for an additional 20 min at 0 °C, at 
which time NMP (18.1 µL, 0.188 mmol) was added dropwise, and the reaction was let to 
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stir for 20 min. At this time, the mixture was cooled to −78 °C and aldehyde (3.27, 27.3 
mg, 0.055 mmol) in 0.1 mL DCM was added dropwise. The vial was washed with an 
additional 0.1 mL. The reaction was stirred at −78 °C for 4 h, and then warmed to −50 °C 
and allowed to stir overnight. After complete consumption of the aldehyde, the reaction 
mixture was quenched with saturated ammonium chloride. The aqueous layer was 
extracted with DCM (3x), and the combined organic layers were washed with brine, dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The crude product mixture 
was purified by silica-gel chromatography (10% EtOAc in hexanes) to give the syn aldol 
product 3.30 as a yellow oil (17.1 mg, 40%). [𝛼]𝐷
26 + 32.2 (c 1, CHCl3). 
1H NMR (400 
MHz, CDCl3) δ 7.37 – 7.26 (m, 5H), 7.07 (dd, J = 8.4, 5.5 Hz, 2H), 6.95 (t, J = 8.6 Hz, 
2H), 5.30 (ddd, J = 10.7, 7.0, 4.1 Hz, 1H), 4.88 (dt, J = 9.2, 4.8 Hz, 1H), 4.27 (dd, J = 10.8, 
5.3 Hz, 1H), 3.87 – 3.81 (m, 1H), 3.73 (d, J = 5.7 Hz, 1H), 3.27 – 3.21 (m, 2H), 3.05 (dd, 
J = 13.2, 10.6 Hz, 1H), 2.81 (d, J = 11.4 Hz, 1H), 2.62 (dd, J = 13.5, 5.0 Hz, 1H), 2.45 (dd, 
J = 13.5, 9.4 Hz, 1H), 2.05 (q, J = 7.2 Hz, 1H), 1.92 (dt, J = 14.8, 7.7 Hz, 1H), 1.86 – 1.67 
(m, 3H), 1.63 – 1.57 (m, 1H), 1.00 – 0.88 (m, 24H), 0.83 (d, J = 6.5 Hz, 3H), 0.17 – 0.05 
(m, 12H).13C NMR (100 MHz, CDCl3) δ 201.8, 175.9, 161.4 (d, 1JCF = 243.7 Hz), 137.0 
(d, 4JCF = 3.2), 136.7, 130.5 (d, 
3JCF  = 7.7 Hz, 2C), 129.5 (2C), 129.0 (2C), 127.3, 115.2 
(d, 2JCF = 21.0 Hz, 2C), 75.2, 74.3, 70.1, 69.6, 50.5, 43.5, 42.1, 37.9, 37.1 (2C), 32.0, 26.2 
(3C), 26.1 (3C), 20.4, 18.6, 18.2, 14.0, 12.8, 11.7, -3.3, -3.8, -4.0, -4.2. HRMS calc’d for 
C41H66FNO4S2Si2 (M+Na)
+ 798.3775, found (M+Na)+ 798.3848. 
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(2S,3R,5R,6S,7R,8S)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5,7-tris((tert-
butyldimethylsilyl)oxy)-2-ethyl-9-(4-fluorophenyl)-6,8-dimethylnonan-1-one (3.31).  
 
To alcohol 3.30 (8 mg, 0.01 mmol) at 0 °C in DCM (88 μL, 0.1 M) was added 2,6-lutidine 
(2.4 μL, .021 mmol) followed by TBSOTf (3.6 μL, 0.016 mmol) dropwise. The reaction 
was warmed to RT and stirred until starting material was consumed, at which time the 
reaction was quenched with saturated NaHCO3 and extracted 3x DCM. The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The crude oil was purified via flash chromatography (0-20% EtOAc in hexanes) to give 
3.31 as a yellow oil (5.2 mg, 58% yield). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.26 (m, 
5H), 7.12 (dd, J = 8.2, 5.6 Hz, 2H), 6.92 (t, J = 8.5 Hz, 2H), 5.21 (ddd, J = 10.7, 6.9, 3.4 
Hz, 1H), 4.80 (dt, J = 8.7, 4.4 Hz, 1H), 4.00 – 3.89 (m, 2H), 3.85 (d, J = 6.9 Hz, 1H), 3.29 
(dd, J = 13.3, 3.7 Hz, 1H), 3.22 (dd, J = 11.4, 6.9 Hz, 1H), 3.04 (dd, J = 13.1, 10.7 Hz, 1H), 
2.82 (d, J = 11.3 Hz, 1H), 2.73 (dd, J = 13.3, 4.2 Hz, 1H), 2.48 (dd, J = 13.2, 10.6 Hz, 1H), 
1.99 (ddd, J = 16.4, 13.6, 6.4 Hz, 2H), 1.91 (t, J = 6.7 Hz, 2H), 1.82 (td, J = 7.2, 2.9 Hz, 
1H), 1.61 (dd, J = 13.8, 6.9 Hz, 1H), 0.92 – 0.83 (m, 36H), 0.09 (d, J = 8.6 Hz, 18H).13C 
NMR (100 MHz, CDCl3) δ 201.0, 175.1, 161.3 (d, 1JCF = 242.9 Hz), 137.4, (d, 4JCF = 3.1 
Hz), 136.9, 130.7 (d, 3JCF = 7.7 Hz, 2C),  129.6 (2C), 129.0 (2C), 127.3, 114.9 (d, 
2JCF = 
21.0 Hz, 2C), 77.4, 71.0, 70.7, 69.8, 51.1, 43.6, 41.7, 41.1, 38.0, 36.8, 31.8, 26.5 (3C), 26.3 
(3C), 25.9 (3C), 20.5, 18.8, 18.6, 18.1, 13.2, 12.1, 9.9, -2.8, -3.0, -3.1, -3.9, -4.0, -4.3. 
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(2S,3R,5R,6S,7R,8S)-3,5,7-tris((tert-Butyldimethylsilyl)oxy)-2-ethyl-9-(4-
fluorophenyl)-6,8-dimethylnonanal (3.32). 
 
To a solution of 3.31 (12.8 mg, .014 mmol) in DCM (0.160 mL, 0.1 M) at −78 °C was 
added DIBAL-H (29 μL, 1 M in DCM) dropwise. The reaction went clear almost 
immediately upon addition of DIBAL-H. When clear, saturated Rochelle’s Salt was added 
and the reaction was allowed to stir at rt for 1 hour. At this time, the aqueous layer was 
extracted with DCM (3x), and the combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated under reduced pressure. The crude reaction mixture was 
purified by manual chromatography (20% EtOAc in hexanes) to yield aldehyde 3.32 as a 
clear oil (9.8 mg, quant.), which was used immediately in the next reaction. 1H NMR (400 
MHz, CDCl3) δ 9.63 (s, 1H), 7.05 – 6.96 (m, 2H), 6.90 – 6.83 (m, 2H), 3.95 (ddd, J = 8.1, 
5.5, 2.4 Hz, 1H), 3.86 – 3.77 (m, 1H), 3.65 (dd, J = 8.0, 1.5 Hz, 1H), 2.57 (dd, J = 13.4, 
4.8 Hz, 1H), 2.40 (dd, J = 13.3, 10.3 Hz, 1H), 2.04 (ddt, J = 10.0, 4.0, 2.0 Hz, 1H), 1.90 – 
1.65 (m, 5H), 1.52 (d, J = 7.0 Hz, 1H), 0.81 – 0.70 (m, 36H), -0.06 (d, J = 1.8 Hz, 18H). 
 
Ethyl di-o-Tolyl Phosphite (3.35). 
 
A solution of o-cresol (6.26 mL, 60.7 mmol) and TEA (8.89 ml, 63.8 mmol) in toluene 
(46.4 mL, 0.67 M) was cooled to 0 °C. Dichloro(ethoxy)phosphane (3.55 mL, 1.67 M in 
diethyl ether, 31.1 mmol) was cannula transferred dropwise. After the addition was 
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complete, the reaction was warmed to rt and allowed to stir overnight. The reaction was 
then filtered through celite, concentrated, and used crude in the next reaction.  
 
Ethyl 2-(bis(o-Tolyloxy)phosphoryl)acetate (3.36). 
 
To phosphite 3.35 at 120 °C was added ethyl bromoacetate (5.19 mL, 46.7 mmol) over 15 
min. The reaction was allowed to stir for 48 h at which time the reaction was cooled, 
concentrated, and purified by CombiFlash (5-25% EtOAc in hexanes) to yield 3.36 as a 
yellow oil (6.344 g, 59 %). NMRs are consistent with reported values.161 1H NMR (400 
MHz, CDCl3) δ 7.29 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 7.3 Hz, 2H), 7.15 – 7.05 (m, 4H), 
4.22 (q, J = 7.1 Hz, 2H), 3.33 (d, J = 21.8 Hz, 2H), 2.25 (s, 6H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.1, 149.0, 131.6, 129.7, 127.3, 125.5, 120.5, 62.1, 35.5, 
16.5, 14.2. 
 
Ethyl (4R,5R,7R,8S,9R,10S,Z)-5,7,9-tris((tert-Butyldimethylsilyl)oxy)-4-ethyl-11-(4-
fluorophenyl)-8,10-dimethylundec-2-enoate (3.33). 
 
To phosphonate ester (33 mg, .095 mmol) at 0 °C in THF (1.0 mL, 7.57 mM) was added 
NaH (3.8 mg, .095 mmol). The slurry was allowed to stir for 15 min, at which time the 
reaction was cooled to –78 °C and aldehyde 3.32 (6.3 mg, 9.2 μmol in 0.2 mL THF) was 
added dropwise. The reaction was slowly warmed to 0 °C over 2 h. Following consumption 
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of starting material, the reaction was quenched with NH4Cl and extracted with 3x EtOAc. 
The combined organic layers were washed with brine, dried over MgSO4, filtered, and 
concentrated. The crude oil was purified by flash chromatography (5% EtOAc in hexanes) 
to yield 3.33 as a clear oil (2.4 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 7.10 (q, J = 7.1, 
5.8 Hz, 2H), 6.95 (td, J = 8.8, 3.7 Hz, 2H), 6.12 (dddt, J = 35.1, 16.2, 10.0, 1.0, 0.5 Hz, 
1H), 5.83 (d, J = 11.7 Hz, 1H), 4.86 – 4.74 (m, 1H), 4.04 – 3.94 (m, 1H), 3.91 – 3.63 (m, 
3H), 3.55 – 3.35 (m, 1H), 2.74 – 2.61 (m, 1H), 2.54 – 2.43 (m, 1H), 2.43 – 2.34 (m, 1H), 
2.00 – 1.85 (m, 3H), 0.07 (s, 18H). Grease is obscuring signals between 1.8 and 0.4. Efforts 
to remove grease were unsuccessful. Attempts to collect a 13C NMR were unsuccessful on 
400 and 700 MHz NMR instruments. Attempts to collect HRMS were unsuccessful. All of 
these characterization data will be completed upon generation of more material.  
 
(5R,6R)-5-Ethyl-6-((2R,3S,4R,5S)-6-(4-fluorophenyl)-2,4-dihydroxy-3,5-
dimethylhexyl)-5,6-dihydro-2H-pyran-2-one (4-fluorophenyldemethylpironetin, 3.2) 
 
To alkene 3.33 (2.4 mg, 2.66 μmol) was added 1% HCl in EtOH (60 μL). The reaction was 
allowed to stir overnight at which time it was diluted with DCM and quenched with 
saturated sodium bicarbonate. The aqueous layer was washed 3 additional times with 
DCM, the combined organic layers washed with brine, dried over MgSO4, filtered, 
concentrated, and purified by flash chromatography (5% EtOAc in hexanes) to yield the 
target molecule, 4-fluorophenyldemethylpironetin (3.2, 0.7 mg, 60%).  1H NMR (400 
MHz, CDCl3) δ 7.16 – 7.10 (m, 2H), 6.98 – 6.91 (m, 2H), 6.39 – 6.31 (m, 1H), 6.25 – 6.16 
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(m, 1H), 4.72 – 4.66 (m, 1H), 3.68 – 3.62 (m, 2H), 3.28 – 3.20 (m, 1H).  Grease is obscuring 
signals between 2.4 and 0.4. Extensive efforts to remove grease were unsuccessful. All 
characterization data will be completed upon generation of more material.  
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5.4 Chapter 4 Synthesis and Evaluation of Pironetin Conjugates 
5.4.1 Synthesis of Conjugates 
N2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(((S)-3-
carboxy-1-(((S)-1-(((S)-3-carboxy-1-(((S)-3-carboxy-1-(((S)-1-carboxy-2-
mercaptoethyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-
guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-L-glutamine (4.3). 
 
Folic acid peptide 4.3 was synthesized by solid phase peptide synthesis at rt starting from 
cysteine modified Wang resin as previously described.147 Briefly, the resin was Fmoc 
deprotected with 20% piperidine in DMF (3x3mL, 5 min each), washed with DMF, and 
swelled with DCM. This allowed for coupling in DMF (3 mL) with PyBop (0.22 mmol), 
DIPEA (0.44 mmol), HoBt (0.22 mmol) and the amino acid of interest (0.22 mmol): Fmoc-
Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, and 
Fmoc-Glu(OtBu). Couplings were followed by Fmoc deprotection, both monitored by the 
Kaiser test. Following successful Glu coupling and Fmoc deprotection, N10-TFA pteroic 
acid (N10-TFA Pte, 0.44 mmol) was coupled. The resulting peptide was treated with 
hydrazine (2% in DMF, 3 mL, 3x5 min) followed by global deprotection and cleavage from 
the resin (92.5% TFA, 2.5% TIPS, 2.5% EDT, 2.5% H2O). After stirring for 1.5 h, the 
cleaved peptide was drained into ice cold Et2O and allowed to precipitate overnight at -20 
°C. Following precipitation, the peptide was pelleted by centrifugation, decanted, and 
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immediately purified by preparative HPLC (A: H2O with 0.1% TFA; B: ACN). MALDI 
calc’d for C40H51N15O17S 1046.00, found 1046.43.  
2-(Pyridin-2-yldisulfaneyl)ethan-1-ol (4.4). 
 
To aldithiol (1 g, 5 mmol) in 10 mL MeOH at rt was added a few drops of acetic acid. β-
Mercaptoethanol (0.160 mL, 2.27 mmol in 4 mL MeOH) was added dropwise and the 
reaction was allowed to stir overnight. The next day, the reaction was concentrated under 
reduced pressure and purified by flash chromatography to yield alcohol 4.4 as a yellow 
solid (462.1 mg, 51%). NMR characterization is consistent with reported values.147 1H 
NMR (400 MHz, CDCl3) δ 8.51 (d, J = 4.9 Hz, 1H), 7.58 (td, J = 7.7, 1.6 Hz, 1H), 7.40 (d, 
J = 8.1 Hz, 1H), 7.15 (m, 1H), 5.70 (bs, 1H), 3.80 (t, J = 5.1 Hz, 2H), 2.95 (m, 2H). HRMS 
calc’d for C7H9NOS2 (M+Na)+ 210.0126, found (M+Na)+ 210.0009. 
 
(2R,3S,4R,5S,E)-1-((2R,3R)-3-Ethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-4-methoxy-
3,5-dimethylnon-7-en-2-yl (2-(pyridin-2-yldisulfaneyl)ethyl) Carbonate (4.5). 
 
To a solution of pironetin (1.1, 10.0 mg, 0.031 mmol) in DCM (0.350 mL) was added 
DMAP (23.0 mg, 0.18 mmol) in one portion. Triphosgene (3.2 mg, 0.011 mmol) was 
carefully added and the reaction immediately turned cloudy. After the reaction went clear 
(about 1 h), alcohol 4.4 (5.8 mg, 0.031 mmol) in DCM (0.150 mL, final concentration 0.06 
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M) was added dropwise. The reaction was allowed to stir at rt overnight, at which time the 
crude reaction was concentrated under reduced pressure and purified by flash 
chromatography (0-20% EtOAc in DCM) to yield activated pironetin (4.5) as a yellow 
solid (16.2 mg, 98% yield). 1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 4.9 Hz, 1H), 7.74 – 
7.61 (m, 2H), 7.13 (td, J = 5.6, 4.9, 2.3 Hz, 1H), 7.00 (dd, J = 9.8, 6.0 Hz, 1H), 6.02 (d, J 
= 9.7 Hz, 1H), 5.51 – 5.33 (m, 2H), 5.19 (td, J = 6.8, 2.0 Hz, 1H), 4.50 (dt, J = 8.4, 4.3 Hz, 
1H), 4.42 (t, J = 6.4 Hz, 2H), 3.41 (s, 3H), 3.08 (t, J = 6.5 Hz, 2H), 2.96 (dd, J = 9.3, 2.3 
Hz, 1H), 2.25 (dt, J = 9.9, 5.1 Hz, 1H), 2.11 (ddt, J = 22.0, 14.8, 6.7 Hz, 2H), 2.03 – 1.93 
(m, 2H), 1.75 (ddd, J = 13.1, 6.5, 2.8 Hz, 2H), 1.65 (s, 3H), 1.51 (ddd, J = 13.5, 8.3, 4.6 
Hz, 2H), 0.96 (d, J = 7.5 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 164.2, 154.9, 150.5, 149.4, 137.8, 130.2, 129.0, 126.7, 121.3, 
121.0, 120.5, 85.3, 77.4, 75.7, 65.4, 61.4, 39.7, 38.5, 37.3, 36.0, 34.5, 29.8, 20.7, 18.2, 12.6, 
11.1, 10.5. HRMS calc’d for C27H39NO6S2 (M+Na)+ 560.2219, found (M+Na)+ 560.2111. 
 
First Generation Pironetin Conjugate (4.2). 
 
To a solution of peptide 4.3 (2.21 mg, 2.1 μmol) in DMSO (30 μL, 0.07 M final 
concentration) was added activated pironetin 4.5 (1.3 mg, 2.4 μmol) in DMSO (10 μL) and 
DIPEA (0.82 μL, 4.7 μmol) by Wiretrol. The reaction was allowed to stir overnight at RT 
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at which time the reaction was quenched with 10% HCl, diluted with ACN until solution 
was clear, and purified by preparative HPLC (A: H2O + 0.1% TFA B: ACN). MALDI 
calc’d for C62H85N15O23S2 1472.56, found 1472.85.  
 
(2S,5S,23S)-23-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-
yl)methyl)amino)benzamido)-5-(carboxymethyl)-2-(mercaptomethyl)-6,20-dioxo-
9,12,15,18-tetraoxa-3,4,19-triazatetracosanedioic Acid (4.8). 
 
Peptide 4.8 was synthesized in the same way as peptide 4.3 except replacing Fmoc-N-
amido-PEG4-acid for Asp-Arg-Asp. Following precipitation, the peptide was pelleted by 
centrifugation, decanted, and immediately purified by preparative HPLC (A: H2O with 
0.1% TFA; B: ACN). MALDI calc’d for C37H50N10O15S (M+Na) 929.92, found 929.54. 
 
Second Generation Pironetin Conjugate (4.9). 
 
Conjugate 4.9 was synthesized in the same way as conjugate 4.2 except using peptide 4.8.  
The reaction was allowed to stir overnight at RT at which time the reaction was quenched 
with 10% HCl, diluted with ACN until solution was clear, and purified by preparative 
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HPLC (A: H2O + 0.1% TFA; B: ACN). MALDI calc’d for C59H84N10O21S2 (M+Na) 
1355.49, found 1355.60.  
 
Camptothecin Conjugate 4.7. 
Synthesis of intermediates and the final conjugate were done according to the literature and 
each compound matched the reported characterization.147 
5.4.2 Characterization of Pironetin Release 
Pironetin or conjugate 4.2 was treated with 10x molar excess of DTT in H2O. After 1 h and 
8 h, the crude sample (50 μL) was injected onto an HPLC equipped with a 5 μm C18 100 
Å, LC Column (150 x 4.6 mm) using (A) water and (B) acetonitrile. Samples were 
maintained at 10 °C and the column was maintained at 25 °C. For analysis, the column was 
allowed to equilibrate at 30% B prior to the injection of sample. Following sample 
injection, the gradient was increased to 99% B over 30 min and held for an additional 6 
min at 99% before reducing to 30% B over 15 min. The gradient was held at 30% B for an 
additional 10 min. Absorbance was monitored at 220, 280, and 354 nm.  
The samples were also injected onto an Agilent MSD SL LC-MS using (A) water + 0.1% 
TFA and (B) acetonitrile. Samples were maintained at 10 °C and the column was 
maintained at 25 °C. For analysis, the column was allowed to equilibrate at 30% B prior to 
the injection of sample. Following sample injection, the gradient was increased to 99% B 
over 30 min and held for an additional 6 min at 99% before reducing to 30% B over 15 
min. The gradient was held at 30% B for an additional 10 min. Samples were monitored 
by MS and by absorbance at 220, 280, and 354 nm.  
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5.4.3 Cell Adaptation to FF Conditions 
IGROV and SKOV cells were acquired from the NIH cell repository and cultured in RPMI 
1640 media supplemented with 10% FBS and pen/strep (+FA media). To adapt to FF 
conditions (FF media), cells were passaged four times at six ratios of +FA media in FF 
media: 100% +FA media, 80% +FA media, 60% +FA media, 40% +FA media, 20% +FA 
media, and 100% FF media (0% +FA media). 
 
5.4.4 Cell Viability Assay 
Cells (IGROV FF and SKOV FF) were grown in a 5% CO2 atmosphere at 37 °C in tissue 
culture dishes. Cells were grown in Folate Free RPMI 1640 media supplemented with 10% 
fetal bovine serum (FBS) and 50 U/mL penicillin/streptomycin. 
Upon ~70% growth confluence, cells were harvested by trypsin and the pellet was washed 
with media and spun down twice before plating 50 μL of 3x104 cells/mL in each required 
well of a 96-well plate. Cells were allowed to grow for 24 h, after which cells were treated 
with 11 concentrations of compound of interest and pironetin as a control. For experiments 
in which FA was added, FA was added to the drug stock solution and the dosing media. 
Cells were then incubated for 1 h and FA containing experiments had media replaced with 
FF media and then incubated for 72 h, or just incubated for 72 h. 
Cell proliferation was analyzed following published protocol for the Non-Radioactive Cell 
Proliferation Assay (MTT). Following individual treatment with compounds, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 15 μL of 12 mM stock) was added 
to the culture medium and allowed to incubate for 4 h at 37 °C. After this time, solubilizing 
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solution/stop mix (150 μL, Promega) was added and the plates were set to incubate 
overnight at 37 °C, after which the absorbance was measured at 570 nm on a microplate 
reader. Each measurement was done in triplicate during each experiment on a minimum of 
two separate experiments.  
 
5.4.5 Internalization Assay 
Upon ~70% growth confluence, IGROV FF and SKOV FF cells were harvested by trypsin 
and the pellet was washed with media and spun down twice before plating 2 mL of 3x104 
cells/mL in each required well of a 6-well plate. Cells were allowed to grow for 24 h, after 
which cells were treated with conjugate, pironetin, or no treatment. Cells were allowed to 
incubate for 2 h, at which time the media was removed, the cells were washed 2x PBS 
buffer (pH 7.4), and lysed (RIPA buffer containing PMSF and protease inhibitor following 
Promega protocol). The cells were scraped into a centrifuge tube, spun down at 20,000 × 
g and the supernatant was collected and extracted 4x EtOAc. The organic layers were dried 
under nitrogen and taken up in 30% acetonitrile in water and immediately injected onto the 
Orbitrap Velos for analysis.  
Prepared metabolism samples were injected onto a NanoLC-Ultra 2D HPLC system 
equipped with a 15 µL injection loop. Separation was performed on a C18 column (Synergi 
2.5 um Max-RP 100 Å column, 100 x 3 mm) using a mobile phase consisting of water + 
0.1% formic acid (A) and acetonitrile + 0.1% formic acid (B) at a flow rate of 400 µL/min. 
The elution gradient conditions are as follows: column was equilibrated in 5% B prior to 
injection. Following sample injection, the gradient was held at 5% B for 1 min and then 
increased to 99% B over 38 min, and then held at 99% B over an additional 4 min. The 
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gradient was reduced to 5% B over an additional min. The gradient was then held for an 
additional 10 min at 5% B. The injected sample volume was 5 µL. 
Samples were analyzed by HPLC-APCI+-MS/MS atmospheric pressure chemical 
ionization (APCI) in positive mode using an LTQ Orbitrap Velos instrument. The APCI 
source was heated at 250 °C. Source voltage was 3.7 kV, sheath gas and auxiliary gas flow 
rates were 30 and 5 arbitrary units, respectively; capillary temperature was 300 °C.  
The LTQ Orbitrap Velos was operated with four scan events. The first scan event was a 
full FTMS scan in positive mode over a mass range of 300-1600 m/z with a resolving power 
of 7500. The second scan event was HCD MS2 fragmentation of the conjugate mass 
(1473.3000 m/z) over a mass range of 200-1500 m/z and with a resolving power of 15000.  
The third scan event was HCD MS2 fragmentation of the pironetin mass (325.2500 m/z) 
over a mass range of 50-400 m/z and with a resolving power of 15000.  The third scan 
event was HCD MS2 fragmentation of the pironetin-GSH adduct mass (632.2000 m/z) over 
a mass range of 100-700 m/z and with a resolving power of 15000. Normalized collision 
energy was set to 50% with an activation time of 0.1 ms.  The data were processed using 
the XCaliber software. 
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